Document:

<PAGE>

                                                                  EXECUTION COPY

                      AMENDED AND RESTATED PROMISSORY NOTE

$7,000,000                                                 Original Issue Date
                                                           December 1, 1999

         AMENDED AND RESTATED PROMISSORY NOTE, dated as of March 1, 2000, by
DUALSTAR TECHNOLOGIES CORPORATION, a Delaware corporation (the "Company"), in
favor of MADELEINE L.L.C., a New York limited liability company (the "Holder"),
for the principal sum of Seven Million Dollars ($7,000,000) with interest
(computed on the basis of a 360 day year and the actual number of days elapsed)
at the rate of 11.0% per annum on the balance of the principal from time to time
remaining unpaid, all on the terms and conditions set forth herein (the "Note").

                                   WITNESSETH:

         WHEREAS, the Company issued a Convertible Promissory Note, dated as of
December 1, 1999 (the "Convertible Note"), in favor of the Holder for the
principal sum of Seven Million Dollars ($7,000,000); and

         WHEREAS, in exchange for the issuance and delivery by the Company to
Cerberus Capital Management, L.P. ("Cerberus") and Blackacre Capital Management
L.L.C. ("Blackacre") of warrants, dated as of December 16, 1999 (the
"Warrants"), entitling Cerberus and Blackacre to purchase from the Company
shares of common stock, par value $.01 per share, of the Company (the "Common
Stock") on such terms described in such Warrants, the Holder agreed to waive its
conversion rights under the Convertible Note and amended and restated the
Convertible Note accordingly as of December 16, 1999 (the Convertible Note, as
so amended and restated is hereinafter referred to as the "Amended Note"); and

         WHEREAS, in consideration of the acceptance and agreement by the
Company to certain amendments, as of March 1, 2000, to that certain letter among
the parties, dated as of December 16, 1999, the Holder has agreed to extend the
Maturity Date of the Amended Note; and

         NOW, THEREFORE, in consideration of the premises and the mutual
agreements hereinafter set forth and for the purpose of defining the terms and
provisions of this Note, the Amended Note is restated below in its entirety, and
the Company and Holder agree as follows:

         FOR VALUE RECEIVED, DUALSTAR TECHNOLOGIES CORPORATION, a Delaware
corporation (the "Company"), promises to pay to MADELEINE L.L.C., a New York
limited liability company (the "Holder"), at 450 Park Avenue, 28th Floor, New
York, New York 10022 or at such other place as the Holder may in writing
designate, the principal sum of Seven Million Dollars ($7,000,000) with interest
(computed on the basis of a 360 day year and the actual number of days elapsed),
from December 1, 1999, at the rate of 11.0% per annum on the balance of the
principal from time to time remaining unpaid, all on the terms and conditions
set forth herein (the "Note").

<PAGE>

         1. Maturity, Interest and Amortization. Unless accelerated pursuant to
the terms of this Note, the unpaid principal balance of this Note together with
all unpaid interest accrued thereon shall be due and payable on May 31, 2000
(the "Maturity Date", with the period of time from the date hereof until the
Maturity Date being referred to herein as the "Term"). Interest on the Note
shall be payable monthly in arrears in cash on the 15th day of each month with
the first payment to be made on December 15, 1999. Principal and interest are
payable in lawful money of the United States. All payments received by Holder
under this Note shall be credited first to any charges or other expenses for
which Holder is entitled to payment hereunder, next to accrued but unpaid
interest, and third to unpaid principal. The Company shall have the right at any
time on at least fifteen (15) days' notice to prepay any portion of the
outstanding principal of this Note without penalty. Notwithstanding any contrary
provision contained herein, (i) immediately upon any Disposition (as such term
is hereinafter defined) by the Company or any of its subsidiaries, the Company
shall prepay the unpaid principal balance of this Note together with all unpaid
interest accrued thereon in an amount equal to 100% of the Net Cash Proceeds (as
such term is hereinafter defined) received by the Company or any of its
subsidiaries or affiliates in connection with such Disposition except to the
extent that such Net Cash Proceeds (x) relate to the sale of High-Rise Electric,
Inc. ("High-Rise") and (y) are used in accordance with a written budget
furnished to Holder within 30 days of the date hereof (and from time to time
thereafter) and approved by Holder, which approval shall not be unreasonably
withheld or delayed; (ii) immediately upon the incurrence by the Company or any
of its subsidiaries of any Indebtedness, the Company shall prepay the unpaid
principal balance of this Note together with all unpaid interest accrued thereon
in an amount equal to 100% of the Net Cash Proceeds received by the Company or
any of its subsidiaries in connection therewith; provided, that any amount of
unpaid principal balance together with unpaid interest which is not prepaid by
the Company pursuant to clause (i) and/or (ii) shall remain an obligation of the
Company on such terms and conditions set forth herein.

         "Disposition" for purposes hereof shall mean any transaction, or series
of transactions, pursuant to which the Company or any of its subsidiaries sells,
assigns, transfers or otherwise disposes of any property or assets (whether now
owned or hereafter acquired) to any other Person, in each case whether or not
the consideration therefor consists of cash, securities or other assets owned by
the acquiring Person, excluding any sales of inventory in the ordinary course of
business on ordinary business terms.

         "Excluded Subsidiary" for the purposes hereof shall mean each of the
following subsidiaries of the Company: Centrifugal Service, Inc.; The Automation
Group, Inc.; Trident Mechanical Systems, Inc.; Property Control, Inc.; Grace
Systems Technologies, Inc.; and HR Electrical Systems, Inc.

         "Indebtedness" for purposes hereof shall mean indebtedness for borrowed
money, but shall not include accounts payable to trade creditors created or
assumed in the ordinary course of business in connection with obtaining
materials or services or amounts owed to employees of the Company in the
ordinary course of business.

         "Net Cash Proceeds" for purposes hereof shall mean (i) with respect to
any Disposition by the Company or any of its subsidiaries, the amount of cash
received (directly or

                                        2
<PAGE>

indirectly) from time to time (whether as initial consideration or through the
payment of deferred consideration) by or on behalf of the Company or any of its
subsidiaries, in connection therewith after deducting therefrom only (A) the
principal amount of any indebtedness secured by any lien on any asset (other
than indebtedness assumed by the purchaser of such asset) which is required to
be, and is, repaid in connection with such Disposition (other than indebtedness
under this Note), (B) reasonable expenses related thereto reasonably incurred by
the Company or any of its subsidiaries in connection therewith, (C) transfer
taxes paid by the Company or any of its subsidiaries in connection therewith and
(D) net income taxes to be paid in connection with such Disposition (after
taking into account any tax credits or deductions and any tax sharing
arrangements and (ii) with respect to the issuance or incurrence of any
indebtedness by the Company or any of its subsidiaries, or the sale or issuance
by the Company or any of its subsidiaries of any shares of its capital stock,
the aggregate amount of cash received (directly or indirectly) from time to time
(whether as initial consideration or through the payment of deferred
consideration) by or on behalf of the Company or any of its subsidiaries in
connection therewith after deducting therefrom only reasonable brokerage
commissions, underwriting fees and discounts, legal fees and similar fees and
commissions.

         1A. Use of Proceeds. The Company shall use Two Million One Hundred
Thirty-Four Thousand One Hundred Fifteen and 57/100s Dollars ($2,134,115.57) of
the principal received pursuant to this Note to pay (or cause
Centrifugal/Mechanical Associates, Inc. ("CMA") to pay) in full to Technology
Investors Group, L.L.C. the amounts owed under (a) the Promissory Note, dated as
of October 26, 1999 (the "1999 TIG Loan"), (b) the Secured Promissory Note
Extension Agreement, dated as of November 25, 1998 (the "1998 TIG Loan") and (c)
the Promissory Note, dated as of July 24, 1998 (the "Additional TIG Loan, and
with the 1999 TIG Loan and 1998 TIG Loan collectively referred to herein as the
"TIG Loans").

         2. Event of Default/Remedies

                  a. Any of the following events shall constitute an Event of
Default:

                           i. (A) any failure to pay when due (whether at stated
maturity, by reason of acceleration of the maturity hereof or otherwise) any
principal hereof or any interest hereon; (B) any material breach by the Company
of any of its other obligations or covenants under this Note, the Guaranties,
the Security Agreement or the Pledge and Security Agreements (as such terms are
hereinafter defined), provided that such breach is not cured by the Company
within ten (10) days from the date of receipt of any notice from Holder of such
breach; or (C) any material breach by CMA, Centrifugal Associates, Inc. ("CA")
or Mechanical Associates, Inc. ("MA") of its obligations or covenants under
their respective guaranties (the "Guaranties") of this Note, or the Security
Agreement (as herein defined); or

                           ii. the Company or any subsidiary (other than an
Excluded Subsidiary) thereof (A) becomes insolvent or admits in writing its
inability to pay its debts as they mature, (B) makes any assignment for the
benefit of creditors, or (C) applies for or consents to the appointment of a
receiver or trustee for the Company or such subsidiary or for a substantial part
of the Company's or such subsidiary's property or business, or a receiver or
trustee otherwise is appointed and is not discharged within 45 days after such
appointment (for purposes of this

                                        3
<PAGE>

subsection, the Company or such subsidiary shall be deemed "insolvent" if, as of
the Company's or such subsidiary's most recent balance sheet, the sum of its
debts exceed the sum of its assets, at a fair valuation, or it is unable to pay
its debts as they come due); or

                           iii. any bankruptcy, insolvency, reorganization or
liquidation proceeding or other proceeding for relief under any bankruptcy law
or any law for the relief of debtors is instituted by or against the Company or
any subsidiary (other than an Excluded Subsidiary), and if against the Company
or any subsidiary (other than an Excluded Subsidiary) such proceeding is not
vacated within 45 days; or

                           iv. any money judgment, lien, writ or warrant of
attachment, or similar process is entered of filed against the Company or any
subsidiary (other than an Excluded Subsidiary) or any of the assets of the
Company or any subsidiary (other than an Excluded Subsidiary) and remains
unvacated, unbonded, unstayed, undismissed or undischarged for a period of 45
days or in any event later than 10 days before the date of any proposed sale
thereunder, provided that such a lien (singly or, if more than one,
cumulatively) of less than $250,000 arising in the ordinary course of the
Company's or any subsidiary's business, even if it remains unbonded, unstayed or
undismissed for 45 days, shall not be deemed an Event of Default if the Company
has been advised by counsel in writing and thus believes in good faith that it
has a valid defense to the claim giving rise to such lien and promptly so
advises Holder in writing and timely contests such claim; or

                           v. the Company or any subsidiary (A) defaults on or
breaches in any material respect any material contract with or obligation when
due to a third party or (B) defaults in the performance of any material
obligation to a third party or Holder incurred for money borrowed of $500,000 or
more; or

                           vi. the Common Stock is delisted from the NASDAQ
National Market System ("NASDAQ"), unless such delisting occurs in connection
with the Common Stock being traded on either the American Stock Exchange or the
New York Stock Exchange; or

                           vii. the acquisition, directly or indirectly, by any
person or group (within the meaning of Section 13(d)(3) of the Securities
Exchange Act of 1934) of beneficial ownership of more than 20% of the aggregate
outstanding voting power of the capital stock of the Company; or

                           viii. individuals who as of the date hereof
constituted the board of directors of the Company (together with any new
directors whose election by such board of directors or whose nomination for
election by the stockholders of the Company was approved by a vote of at least
66 2/3% of the directors of the Company then still in office who were either
directors as of the date hereof, or whose election or nomination for election
was previously so approved) cease for any reason to constitute a majority of the
board of directors of the Company then in office;

                           ix. the Company shall fail to comply with the
provisions of Section 1A hereof;

                                        4
<PAGE>

                           x. the Company shall fail to perform in a timely
manner its obligations (or disclaim any obligations) pursuant to that certain
letter of intent (the "Proposal Letter"), dated December 1, 1999, heretofore
executed and delivered by and among the Company, Cerberus and Blackacre (with
such changes thereto as Cerberus and Blackacre shall agree to in their sole
discretion); or

                           xi. the Company shall fail to perform in a timely
manner its obligations (or shall disclaim any obligations) pursuant to that
certain letter, dated as of December 16, 1999, from the Company to Cerberus and
Blackacre, regarding the payment of certain amounts in connection with a
"Competing Transaction" (as defined therein).

                  b. Remedies. Upon the occurrence and during the continuance of
an Event of Default described in subsections 2(a)(i)(A), 2(a)(ii), 2(a)(iii),
2(a)(x) or 2(a)(xi) above, all indebtedness under this Note shall automatically
be immediately due and payable. Upon the occurrence and during the continuance
of any other Event of Default, Holder at its option and, unless otherwise
specified below, upon no less than five (5) business days' written notice to the
Company (or such other notice as is required by law), may do any one or more of
the following:

                           i. declare all indebtedness under this Note
immediately due and payable and credit any sums received thereafter to such
indebtedness in whatever priority it shall elect; provided, however, that
application of sums so received shall not serve to waive or cure any default
existing under this Note nor to invalidate any notice of default or any act done
pursuant to such notice and shall not prejudice any rights of Holder; and

                           ii. exercise any or all rights provided or permitted
by law or granted pursuant to this Note, the Guaranties or that certain Pledge
Agreement, dated November 30 1999, by and between the Company and Holder
relating to all of the common stock of CA, MA and High-Rise, and the Pledge and
Security Agreements, dated as of November 30, 1999, by and between CA and MA and
the Holder relating to all of the common stock of CMA (collectively, the "Pledge
and Security Agreements") and that certain Security Agreement, dated as of
November 30, 1999, by and between CMA and the Holder (the "Security Agreement"),
in such order and in such manner as Holder may, in its sole judgment, determine,
including without limitation its right to convert this Note to Common Stock
pursuant to Section 5 hereof; provided that, upon conversion in accordance with
the terms hereof, Holder shall not have or exercise any other rights or remedies
hereunder, other than with respect to claims relating to the calculation or
payment of interest or costs and expenses of collection pursuant to Section 8
hereof, that have arisen up to the time of or in connection with conversion.

         3. Default Rate. Any amounts not paid when due shall thereafter bear
interest at a rate per annum equal to the 18.0%. If such default rate would but
for this sentence, exceed the maximum lawful rate, the effective interest rate
under this Note shall be the maximum lawful rate, and any amount received by
Holder in excess of such rate shall be applied to principal and then to fees and
expenses, or, if no such amounts are owing, returned to the Company.

                                        5

<PAGE>
         4. Waiver. The Company hereby waives any right of offset it may now or
hereafter have against Holder, and the Company hereby also waives diligence,
presentment, protest and demand, notice of protest, dishonor and nonpayment of
this Note and expressly agrees that, without in any way affecting the liability
of the Company hereunder, Holder may in its sole discretion extend any maturity
date or the time for payment of any installment due hereunder, accept security,
release any party liable hereunder and release any security hereafter securing
this Note.

         5. [Intentionally omitted.]

         6. Notices. Any notice required by the provisions of this Note shall be
in writing and shall be deemed effectively given: (i) upon personal delivery to
the party to be notified, (ii) when sent by confirmed telex or facsimile, (iii)
five (5) days after having been sent by registered or certified mail, return
receipt requested, postage prepaid, or (iv) two (2) days after deposit with a
nationally recognized overnight courier, with written verification of receipt.
All notices shall be addressed to Holder at 450 Park Avenue, 28th Floor, New
York, New York 10022, Attention: Mark A. Neporent or at such subsequent address
as Holder shall provide to the Company in writing. Any notice to the Company
shall be addressed to the Company at 11-30 47th Avenue, Long Island City, New
York 11101 or at such subsequent address as the Company shall provide to the
Holder in writing.

         7. Covenants. So long as the principal balance of the Note remains
outstanding, without the consent of the Holder, the Company agrees as follows
(the "Covenants"):

                  (i) The Company will not alter, amend or modify in any respect
the rights, preferences or privileges of the Note.

                  (ii) The Company and its subsidiaries will not incur any
Indebtedness.

                  (iii) The Company and its subsidiaries shall not engage in any
Disposition unless at least 65% of the proceeds thereof consist of cash and the
Net Cash Proceeds thereof are applied to the prepayment of the Note or otherwise
applied in accordance with Section 1 of this Note.

                  (iv) The Company and its subsidiaries (other than any Excluded
Subsidiary) shall not make, or commit to make, any Investment(s) in any Excluded
Subsidiary in excess of $20,000 in the aggregate. "Investments" for purposes
hereof shall mean all investments in the forms of direct or indirect loans
(including guarantees of Indebtedness or other obligations), advances or capital
contributions, purchases or other acquisitions for consideration of
Indebtedness, equity interests (including, without limitation, capital stock,
warrants, options or other rights to acquire capital stock) or other securities,
together with all other items that are or would be classified as investments on
a balance sheet prepared in accordance with generally accepted accounting
principles.

                                        6
<PAGE>

         No reference contained herein to actions that the Company may take
shall be deemed in any way to prejudice or limit Holder's rights to enforce the
Covenants. The Company acknowledges that the Covenants are a material inducement
to Holder's willingness to purchase the Note, and that Holder would not be
willing to purchase the Note in the absence of the Covenants. Accordingly,
except to the extent that the Covenants expressly limit Holder's discretion, the
Company acknowledges that Holder shall be free to enforce the Covenants in its
absolute discretion or to condition its consent as it sees fit.

         8. Legal Fees. The Company agrees to pay all Holder's reasonable costs
and expenses actually incurred by Holder in connection with the good faith
enforcement of any obligation of the Company under this Note, including without
limitation reasonable attorneys' fees.

         9. Governing Law. This Note shall be governed by and construed in
accordance with the laws of the State of New York.

         [Remainder of this page intentionally left blank.]

                                        7
<PAGE>

         10. Severability. Should any provision or portion of this Note be held
unenforceable or invalid for any reason, the remaining provisions and portions
of this Note shall be unaffected by such holding.

DUALSTAR TECHNOLOGIES CORPORATION

By: /s/ ROBERT BIRNBACH
   ------------------------------

Its: CFO & EVP
    -----------------------------

MADELEINE L.L.C.

By: /s/ MARK NEPORENT
   ------------------------------

Its: Authorized Signatory
    -----------------------------

                                        8<PAGE>   1
                                                                    EXHIBIT 10.8

                        CONFIDENTIAL TREATMENT REQUESTED

         Confidential Portions of This Agreement Which Have Been Redacted Are
Marked With Brackets ("[***]"). The Omitted Material Has Been Filed Separately
With The Securities and Exchange Commission.

                    PRODUCT DEVELOPMENT AND SUPPLY AGREEMENT

         THIS AGREEMENT (the "Agreement") is entered into as of March 25, 1999
(the "Effective Date") by and between Penwest Pharmaceuticals Co., a Washington
corporation with a principal place of business at 2981 Route 22, Patterson, New
York 12563 ("Penwest"), and Horizon Pharmaceutical Corporation, a Delaware
corporation with a principal place of business at 660 Hembree Parkway, Suite
106, Roswell, Georgia 30076 ("Horizon").

         A. Whereas Penwest has developed a controlled-release agent covered by
one or more patents, patent applications, know-how and other proprietary
technology, which agent Penwest markets under the name "TIMERx" ("TIMERx"), and
Penwest is the owner of certain patents covering controlled release formulations
of the active ingredient [***];

         B. Whereas Horizon is interested in developing for manufacture and
marketing a pharmaceutical product incorporating [***] in a solid-dosage
controlled-release delivery system for oral administration in humans; and

         C. Whereas the parties desire to engage in certain research,
development, and testing activities designed to determine if Penwest's TIMERx
controlled-release system can be adapted and combined with [***] to make a
controlled-release version of [***] for oral solid-dosage administration in
humans in a 24 hour release form in a 200 mg dosage strength and, if such
activities are successful, Horizon desires to contract for a supply of TIMERx
for use in the manufacture of such a controlled-release form of [***], and
Penwest is willing to supply the same, provided that Horizon agrees to obtain
all of its requirements for controlled-release agents for [***] products in the
form of TIMERx from Penwest as provided herein;

         NOW, THEREFORE, the parties hereby agree as follows:

1.       DEFINITIONS.

         1.1 "Affiliate" shall mean any corporation, company, partnership, joint
venture and/or firm which controls, is controlled by, or is under common control
with a specified person or entity. For purposes of this Section 1.1, "control"
shall mean (a) in the case of corporate entities, direct or indirect ownership
of at least fifty percent (50%) of the stock or shares having the right to vote
for the election of directors, and (b) in the case of non-corporate entities,
direct or indirect ownership of at least fifty percent (50%) of the equity
interest with the power to direct the management and policies of such
non-corporate entities.

                                      -1-
<PAGE>   2

                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

         1.2 "Approval Date" shall mean the date on which the Designated Product
is first approved by the FDA for commercial sale in oral solid-dosage form for
administration in humans, pursuant to an NDA.

         1.3 "Capable Entity" shall mean any third party that, in Penwest's
reasonable judgment, (a) has, as applicable, (i) a sales force in the Exclusive
Territory that exceeds Horizon's sales force therein, (ii) annual sales that
exceed those of Horizon, (iii) a financial capacity to market the Designated
Product that exceeds that of Horizon and (iv) a capacity to manufacture the
Designated Product in finished form that exceeds that of Horizon, and (b) does
not manufacture, market or promote any oral, controlled-release drug delivery
product.

         1.4 "Certification Period" shall mean the period beginning on the
Submission Date and ending on the earlier of:

                  1.4.1 the Approval Date; or

                  1.4.2 the termination of this Agreement as provided herein.

         1.5 "Confidential Information" shall mean all information, technology
and know-how disclosed hereunder that is, at the relevant time hereunder,
protected or required to be protected by both parties hereto as confidential
information pursuant to Article 8 hereof.

         1.6 "Covered Infringement" shall have the meaning set forth for such
term in Section 9.1.

         1.7 "Designated Product" shall mean the solid-dosage form of a
controlled-release pharmaceutical for oral administration in humans that
combines a racemic mixture of [***] with TIMERx and other excipients, as more
fully described in Exhibit A, which exhibit is subject to modifications as
Penwest and Horizon may mutually agree during the Development Period.

         1.8 "Development Period" shall mean the period from the Effective Date
through the Submission Date or the earlier termination of this Agreement as
provided herein.

         1.9 "Development Tasks" shall have the meaning set forth for such term
in Section 3.4.

         1.10 "DMF" shall mean Drug Master File with respect to Formulated
TIMERx as defined in 21 CFR 300 et seq., including amendments and supplements
which will be filed by Penwest.

         1.11 "FDA" shall mean the U.S. Food and Drug Administration.

         1.12 "Formulated TIMERx" shall mean TIMERx and certain additives in a
formulation to be developed hereunder specifically for use in the Designated
Product.

         1.13 "Horizon Test and Regulatory Data" shall mean any and all test
data, test designs and protocols, clinical studies and results thereof,
government licenses and applications therefor, government certifications and
findings, and related materials, information and rights (including without
limitation information regarding bioavailability and bioequivalence, and any
adverse drug reactions), developed, commissioned or otherwise obtained by
Horizon or any of its Affiliates or sublicensees during the term of this
Agreement (or, with respect to such sublicensees, during the term of the
respective sublicenses) relating to TIMERx, TIMERx Improvements, the Designated
Product, Penwest Patents, Penwest Technology, and/or Penwest's Confidential
Information, together with all intellectual property and other rights and
interests of Horizon and its Affiliates or sublicensees thereto and therein,
worldwide.

         1.14 "Horizon Trademarks" shall mean trademarks which are the exclusive
property of and which shall remain at all times the exclusive property of
Horizon or its Affiliates.

                                      -2-
<PAGE>   3

         1.15 "IMS Data" shall mean data published in the IMS Retail
Perspective(TM), published by IMS America, Ltd.

         1.16 "IND" shall mean an investigational new drug application filed
with the FDA.

         1.17 "Inpharmakon" shall mean Inpharmakon Corporation.

         1.18 "Indication" shall mean the treatment and/or prophylaxis of
migraine.

         1.19 "Joint Developments" shall mean any and all inventions,
improvements, modifications, alterations, or enhancements, other than TIMERx
Improvements, that are made jointly by Horizon or any of its Affiliates or
sublicensees, on the one hand, and Penwest or any of its Affiliates or
sublicensees, on the other hand, in the course of this Agreement, together with
all United States and foreign intellectual property and other rights and
interests of the parties and their respective Affiliates thereto and therein,
including without limitation patents, trade secrets, copyright, periods of
market exclusivity, and other related rights or interests, to the extent the
same remain protected by any such rights and interests from being used freely by
others; provided, however, that none of the Penwest Test and Regulatory Data or
Horizon Test and Regulatory Data shall be considered Joint Developments.

         1.20 "License Term" shall mean the cumulative period covered by the
Development Period, the Certification Period, and the Marketing Period.

         1.21 "Marketing Period" shall have the meaning set forth for such term
in Section 5.1.

         1.22 "Minimum Sales" shall have the meaning set forth for such term in
Exhibit G.

         1.23 "NDA" shall mean a new drug application filed with the FDA.

         1.24 "Net Sales" shall have the meaning set forth for such term in
Exhibit B.

         1.25 "Penwest Patents" shall mean:

                  1.25.1 those patents and patent applications listed in Exhibit
C and all divisions, continuations, reissues, or extensions thereof, any periods
of marketing exclusivity relating thereto, and any letters patent that issue
thereon; and

                  1.25.2 Penwest's rights in and to any United States patents or
patent applications other than those included in Section 1.20.1, obtained and in
force during the License Term covering any inventions included in the Penwest
Technology.

         1.26 "Penwest Technology" shall mean any technology and know-how
belonging to Penwest from time to time during the term of this Agreement that
directly relate to, and/or are necessary for the production of, the Designated
Product, and Penwest's rights therein and thereto.

         1.27 "Penwest Test and Regulatory Data" shall mean any and all test
data, test designs and protocols, clinical studies and results thereof,
government licenses and applications therefor, government certifications and
findings, and related materials, information and rights (including without
limitation information regarding bioavailability and any adverse drug
reactions), developed, commissioned or otherwise obtained by Penwest or any of
its Affiliates during the term of this Agreement relating to TIMERx, Penwest
Patents, Penwest Technology, and/or Penwest's Confidential Information, together
with all intellectual property and other rights and interests of Penwest and its
Affiliates thereto and therein in the Territory.

                                      -3-
<PAGE>   4

         1.28 "Penwest Trademark(s)" shall mean those names, symbols and/or
characters described in Exhibit D hereto, as the same may be amended from time
to time during the terms of this Agreement by Penwest on at least six (6)
months' prior written notice to Horizon, that are owned and registered (or are
registrable) by Penwest and that have been designated by it for use in
conjunction with Horizon's packaging and promotion of the Designated Product
hereunder, pursuant to Section 6.10.

         1.29 "Project Contact(s)" shall mean the persons appointed by each
party to serve as contact persons between the parties during the Development
Period and the Certification Period. The initial Project Contact for Penwest is
Mr. Michael Mallon and the initial Project Contact for Horizon is Mr. Bala
Venkataraman. Each party shall promptly notify the other party of any
substitution of other personnel as its Project Contact. Each party may select
and supervise its other project staff as needed.

         1.30 "Royalties" (or "Royalty") shall mean the royalties payable to
Penwest pursuant to Article 5 hereof.

         1.31 "Sales Differential" shall have the meaning set forth for such
term in Section 11.2.2.

                                      -4-
<PAGE>   5

                                          [***]-CONFIDENTIAL TREATMENT REQUESTED

         1.32 "Specifications" shall mean such standards and analytical methods
established and mutually agreed to in writing by Penwest and Horizon as are
reasonably necessary or appropriate to assure the identity, strength, quality
and purity of the TIMERx and Formulated TIMERx, as set forth in Exhibit E, which
(a) shall be mutually agreed to by the parties hereto, and (b) may be modified
from time to time by mutual agreement of the parties hereto.

         1.33 "Submission Date" shall mean the date on which Horizon submits to
the FDA an NDA for the Designated Product (in any dosage strength).

         1.34 "Territory" shall mean Canada, the United States, Mexico and their
respective territories and possessions.

         1.35 "TIMERx Improvements" shall mean any and all improvements,
modifications, alterations, or enhancements to any of the inventions covered by
the Penwest Patents or included in the Penwest Technology or Penwest's
Confidential Information, that are developed, owned, or controlled by Horizon or
any of its Affiliates or sublicensees, either alone or jointly with Penwest or
any of its Affiliates or sublicensees, or in which Horizon or any of its
Affiliates or sublicensees otherwise has any rights or interests during the term
of this Agreement (or, with respect to such sublicensees, during the term of the
respective sublicenses) together with all United States and foreign intellectual
property and other rights and interests of Horizon and its Affiliates and
sublicensees thereto and therein, including without limitation patents, trade
secrets, copyright, periods of market exclusivity, and other related rights or
interests, to the extent the same remain protected by any such rights and
interests from being used freely by others.

         1.36 "Unit Price" shall mean [***] U.S. dollars (US$[***]) per kilogram
of Formulated TIMERx, subject to adjustment no more often than once annually to
reflect any increase in the Pharmaceutical Producers' Price Index.

2.       GRANT OF LICENSES AND TRANSFER OF TECHNOLOGY.

         2.1      GRANTS BY PENWEST.

                  2.1.1 Penwest hereby grants to Horizon an exclusive,
royalty-bearing license, under the Penwest Patents, the Penwest Technology, the
Joint Developments, the TIMERx Improvements and Penwest's Confidential
Information disclosed to Horizon hereunder, to manufacture, use and sell and
register the Designated Product in the Territory during the License Term. Such
license does not extend to (a) the making of TIMERx or Formulated TIMERx, but
does cover the incorporation of Formulated TIMERx into the Designated Product,
or (b) any metabolite, isolated enantiomer or non-racemic mixture of [***].
Horizon shall have the right to grant sublicenses of its rights hereunder to any
Affiliate(s) of Horizon (and this Agreement shall thereby be binding upon and
inure to the benefit of such Affiliate(s) within the area of such sublicense),
but shall otherwise have no right to grant sublicenses hereunder without the
prior written consent of Penwest. Such consent of Penwest shall be based on
whether, as of the time the proposed sublicense is to be granted, the proposed
sublicensee is a Capable Entity, unless Horizon is able to demonstrate to
Penwest's reasonable satisfaction that such proposed sublicensee, based on the
particular characteristics of such proposed sublicensee, including but not
limited to the region of the Territory in which such proposed sublicensee would
operate, is a suitable sublicensee despite its failure to qualify as a Capable
Entity. Penwest shall, throughout the License Term, promptly notify Horizon of
all Penwest Patents referred to in Section 1.20.2 and provide Horizon with
access to all of the same, solely for use within the scope of the license stated
in this section.

                  2.1.2 Penwest hereby grants to Horizon and its Affiliates
(with the right to sublicense only as such right is granted under Section 2.1.1)
a nonexclusive, paid-up license under all rights of

                                      -5-
<PAGE>   6

Penwest and its Affiliates in and to the Penwest Test and Regulatory Data to use
the same as is necessary for purposes of complying with governmental
requirements, but solely with respect to the Designated Product for marketing or
use in the Territory. Penwest hereby consents to Horizon's and its Affiliates'
and such sublicensees' cross-referencing the DMF as is necessary for the filing
of an NDA for the Designated Product hereunder.

                  2.1.3 Penwest hereby grants to Horizon and its Affiliates an
exclusive license (with the right to sublicense only as such right is granted
under Section 2.1.1) under any and all rights of Penwest in and to the Penwest
Trademark(s), to use the Penwest Trademark(s) solely in connection with the
manufacture, distribution, and sale of the Designated Product in the Territory
for the term of this Agreement.

         2.2      GRANTS BY HORIZON.

                  2.2.1 Horizon hereby grants to Penwest and its Affiliates a
nonexclusive, paid-up, license, with the right to sublicense, under any and all
patents, patent applications, trade secrets, copyrights, and other intellectual
property rights of any sort owned or controlled by Horizon or its Affiliates or
sublicensees, to make and have made anywhere in the world, and to use and sell
to Horizon and its Affiliates and permitted sublicensees Formulated TIMERx for
use in the Designated Product during the License Term, if and to the extent such
license is necessary for Penwest to do so as agreed hereunder.

                                      -6-
<PAGE>   7

                                          [***]-CONFIDENTIAL TREATMENT REQUESTED

                  2.2.2 Horizon shall grant to Penwest and its Affiliates a
nonexclusive, paid-up license, with the right to sublicense, under all rights of
Horizon and its Affiliates and sublicensees in and to that portion of the
Horizon Test and Regulatory Data that is disclosed or provided to Penwest
hereunder, granting to Penwest the right to use the same for purposes of
complying with governmental requirements of any country, other than with respect
to the Designated Product for marketing or use in the Territory. Horizon shall
consent to Penwest's and its Affiliates' and sublicensees' cross-referencing, in
any filings that are essentially the equivalent of the sorts of filings that are
termed NDA filings if made with the FDA, made by them within the scope of such
license, any NDA filing made or FDA master file created by Horizon or its
Affiliates or sublicensees relating to or containing any of the Horizon Test and
Regulatory Data. Such license under this Section 2.2.2 shall survive any
termination or expiration of the term of this Agreement, except a termination
under Section 11.5 due to an uncured breach by Penwest. Horizon shall,
throughout the License Term and solely for use within the scope of such license,
promptly provide to Penwest copies of all of the Horizon Test and Regulatory
Data in or coming into Horizon's possession or otherwise reasonably available to
it.

         2.3 PENWEST TECHNOLOGY TRANSFER TO HORIZON. Penwest shall, at its
expense, exert reasonable efforts to make knowledgeable personnel reasonably
available within thirty (30) days from the date of Horizon's written request, to
consult with Horizon to the extent necessary to enable Horizon to produce
Designated Product for Horizon and its Affiliates pursuant to this Agreement;
provided, however, that Horizon shall reimburse Penwest, at the rate of one
thousand U.S. dollars (US$1,000) per person per day, for Penwest personnel costs
associated with any such consultation that is not performed at Penwest. The
parties understand and agree that Horizon's performance under this Agreement
depends upon the communication of the Penwest Technology, and that, if for any
reason, it is not possible to transfer such technology to Horizon, this will not
lead to liability on Horizon's part. The Penwest Technology will be deemed to
have been successfully transferred upon completion of scale-up on
production-scale equipment and demonstration of dissolution results comparable
to those obtained for pilot scale batches.

         2.4 PRODUCT DEVELOPMENT OUTSIDE THE TERRITORY. In the event that,
during the License Term, either party hereto approaches the other party with a
proposal that development of the Designated Product be undertaken outside the
Territory, such other party agrees to reasonably consider negotiating a separate
agreement with such party concerning such development, provided that any such
negotiation shall take into account a variety of factors including but not
limited to the parties' respective costs relating to, and proceeds realized
from, the development of the Designated Product.

         2.5      HORIZON'S RIGHTS WITH RESPECT TO OTHER TIMERX PRODUCTS.

                  2.5.1 During the License Term, with respect to any product
that (a) is not the Designated Product and (b) combines TIMERx and [***], not
including any metabolite, isolated enantiomer or non-racemic mixture of [***]
for any therapeutic or prophylactic use(s) in humans, Penwest and Horizon agree
to discuss collaborations concerning the development and commercialization of
such product in the Territory. When Penwest recognizes the possibility for
developing any such product, it shall present such information to Horizon in
writing and Horizon shall have a period of forty-five (45) days in which to
initiate good faith negotiations concerning a potential collaboration with
respect to such product. If Horizon initiates such negotiations, the parties
shall have a period of ninety (90) days in which to execute a definitive
agreement, the terms and conditions of which shall govern any collaboration
between the parties with respect to such product. If either (a) a negotiation
concerning a potential collaboration with respect to any such product is not
initiated, or (b) the parties cannot agree to the terms of a collaboration witH
respect to such product, then Penwest shall have the exclusive right, either
alone or in collaboration with a third party, to undertake the development and
commercialization of

                                      -7-
<PAGE>   8

                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

such product, unless (i) such product is for use for the Indication or (ii)
Horizon demonstrates to Penwest's reasonable satisfaction that such product is
likely to be used off-label for the Indication, in which case Penwest shall not
have the right, either alone or in collaboration with a third party, to
undertake the development and commercialization of such product in the
Territory.

                  2.5.2 During the License Term, with respect to any product
that (a) is not the Designated Product and (b) combines TIMERx and any
metabolite, isolated enantiomer or non-racemic mixture of [***] for any
therapeutic or prophylactic use(s) in humans, Penwest agrees promptly to notify
Horizon in writing when Penwest recognizes the possibility for developing such
product in the Territory. Horizon shall have a period of forty-five (45) days
following such notification in which to provide to Penwest a written request
that Penwest refrain from pursuing the development and commercialization of such
product in the Territory. If (a) Horizon makes such request and (b) (i) such
product is for use for the Indication or (ii) within thirty (30) days following
Penwest's receipt of such request, Horizon demonstrates to Penwest's reasonable
satisfaction that such product is likely to be used off-label for the Indication
in the Territory, Penwest shall refrain from pursuing the development and
commercialization of such product in the Territory either on its own or with a
third party. If Horizon (a) fails to provide such request or (b) makes such
request but (i) such product is not for the Indication or (ii) Horizon fails to
make such demonstration, then Penwest shall have the right to pursue the
development and commercialization of such product in the Territory either on its
own or with a third party.

         2.6 PENWEST USE OF TIMERX. Horizon acknowledges that (a) subject to
other provisions of this Agreement, Penwest and its Affiliates, for themselves
and for others, apply, and will seek to apply, TIMERx and Formulated TIMERx to
products in and outside of the Territory and (b) subject to Sections 2.5.1 and
2.5.2, no provision hereof, and no exclusivity hereunder, shall prevent Penwest
from so applying TIMERx, Formulated TIMERx or other oral, controlled release
drug delivery technology, so long as the end product is not the Designated
Product hereunder for commercial use and/or sale in the Territory; provided,
however, that, subject to Sections 2.5.1 and 2.5.2, Penwest hereby affirms that,
in the Territory, neither it nor its Affiliates shall apply, for themselves or
for others, TIMERx, Formulated TIMERx or other oral, controlled release drug
delivery technology to products containing [***].

         2.7 COMMERCIALLY REASONABLE EFFORTS. During License Term, each of
Penwest and Horizon shall exert their continuing commercially reasonable efforts
to perform their respective tasks hereunder in order to create and produce the
Designated Product, and each shall cooperate with the other in such efforts. It
is understood that the exertion of a party's commercially reasonable efforts
shall mean that this project will receive a priority at least as high as any of
such party's other drug development efforts. Each party shall, promptly and
throughout the term of this Agreement, provide to the other all necessary
information in or coming into its possession or reasonably available to it for
such purposes. Notwithstanding anything else to the contrary contained herein,
nothing shall require either party to disclose confidential information for
which such party has an obligation of confidentiality to a third party.

3.       DEVELOPMENT PERIOD.

         3.1 INITIAL FEE. In consideration of Penwest's entering into this
Agreement, Horizon shall pay Penwest two (2) non-refundable, non-creditable
payments of [***] U.S. dollars (US$[***]) each, (a) the first such payment to be
made on the Effective Date, and (b) the second such payment to be made within
seventy-five (75) days following the Effective Date.

         3.2 NON-COMPETITION BY HORIZON. As additional inducement to Penwest to
enter into this Agreement, Horizon hereby affirms that, other than (a)
confidentiality agreements not binding either

                                      -8-
<PAGE>   9

                                          [***]-CONFIDENTIAL TREATMENT REQUESTED

party to any further agreement and (b) that certain Collaboration Agreement
between Horizon and Inpharmakon, dated October 31, 1998, it currently has no
agreement or arrangement with any party other than Penwest for or including the
development, design, testing, certification, manufacture or marketing by it or
such other party (or the Affiliate(s) of either) in the Territory of any
controlled-release product that incorporates [***], and agrees that it will
refrain from entering into any such agreement or arrangement (other than such
confidentiality agreements) for the term of this Agreement.

         3.3 DEVELOPMENT PERIOD OBLIGATIONS. Each party understands and agrees
that the other does not warrant or commit that the Designated Product will be
successfully developed, and neither party shall have any liability or
responsibility to the other or to third parties for any such failure of the
development process hereunder, except to the extent such failure results from
said party's intentional misconduct, gross negligence, or material breach of its
duties or obligations as set forth herein.

         3.4 DEVELOPMENT PERIOD SCHEDULE AND MILESTONES. During the Development
Period, Penwest and Horizon shall use their commercially reasonable efforts to
perform their respective tasks set forth in the Development Tasks and Success
Criteria contained in Exhibit F hereto (the "Development Tasks") within the
estimated time periods set forth for such tasks therein in order to create and
produce the Designated Product. (The schedule laid out in Exhibit F shall serve
as a general guide for the parties' personnel in pursuing such tasks, but,
except as provided in Section 11.2, strict conformance to such schedule shall
not be an independent criterion of success.) Each party shall bear its own costs
associated with the Development Tasks, except as is otherwise specified in
Exhibit F and Section 3.7. The parties hereby agree to the following:

                  3.4.1 Within [***] days following the successful completion of
preformulation, formulation, dissolution testing, and biostudy formulation
finalization with respect to the Designated Product, Horizon shall pay Penwest a
non-refundable, non-creditable milestone payment of [***] U.S. dollars
(US$[***]).

                  3.4.2 Within [***] days following the successful completion of
a proof-of-principal biostudy for the Designated Product, Horizon shall pay
Penwest a non-refundable, non-creditable milestone payment of [***] U.S. dollars
(US$[***]).

         3.5 GOVERNMENTAL REQUIREMENTS. Subject to Section 2.4, in all countries
of the Territory where the Designated Product is being developed, manufactured,
used and/or sold by Horizon, its Affiliates and/or sublicensees, Horizon shall
be responsible for, and hereby agrees to conduct or arrange for, at the expense
of Horizon, substantial compliance with all material and relevant governmental
requirements imposed in the Territory with respect to such development,
manufacture, use, and/or sale.

         3.6 REPORTS BY PROJECT CONTACTS. Each party's Project Contact shall
provide written reports to the other party's Project Contact at least monthly
throughout the Development Period, stating in detail all efforts made and in
process, and all significant progress achieved and difficulties encountered in
the development effort since the last such report. Each party's Project Contact
shall also be available throughout the Development Period to answer any
reasonable questions from the other party's Project Contact. The parties shall
cooperate reasonably during the Development Period such that the sites for
meetings among their respective personnel shall be alternated between the
parties' facilities to the extent practicable.

         3.7 SUPPLY OF MATERIALS. The price for any Formulated TIMERx purchased
by Horizon from Penwest during the Development Period shall be determined as set
forth in Section 6.2. Penwest shall supply, at its own expense, all TIMERx that
it requires for the conduct of its own Development

                                      -9-
<PAGE>   10

                                          [***]-CONFIDENTIAL TREATMENT REQUESTED

Period activities hereunder. Penwest shall manufacture, at its own expense, a
clinical batch of the Designated Product for the first proof-of-principal
biostudy. Horizon shall pay to Penwest [***] U.S. dollars (US$[***]) for each
clinical batch of the Designated Product for any additional proof-of-principal
biostudy.

4.       CERTIFICATION PERIOD.

         4.1 FILING OF NDA. During the Certification Period, Horizon shall be
responsible for the preparation of all documentation necessary for the filing of
an NDA for the Designated Product and shall file such NDA. Each party
understands and agrees that the other does not warrant or commit that the
Designated Product will be successfully certified for marketing by the FDA, and
neither party shall have any liability or responsibility to the other or to
third parties for any such failure of the certification process hereunder,
except to the extent such failure results from said party's intentional
misconduct, gross negligence, or material breach of its duties or obligations as
set forth herein.

         4.2 CERTIFICATION PERIOD MILESTONES. Horizon agrees to pay Penwest,
within [***] days following the filing by Horizon of an NDA for the Designated
Product, a non-refundable, non-creditable milestone payment of [***] U.S.
dollars (US$[***]).

         4.3 REPORTS BY PROJECT CONTACTS. Horizon's Project Contact shall
provide written reports to Penwest's Project Contact at least quarterly
throughout the Certification Period, stating in reasonable detail all efforts
made and in process, and all significant progress achieved and difficulties
encountered in the certification effort since the last such report. Horizon's
Project Contact also shall be available throughout the Certification Period to
answer any reasonable questions from Penwest's Project Contact.

         4.4 SUPPLY OF MATERIALS. During the Certification Period, Horizon shall
provide, at its own expense, all [***] and other materials and manufacturing and
testing services reasonably required to support the testing and certification
effort. Horizon shall purchase from Penwest, in accordance with the terms set
forth in Section 6.2, all Formulated TIMERx that Horizon requires for the
conduct of Horizon's Certification Period activities hereunder. Penwest shall
supply, at its own expense, all TIMERx that it requires for the conduct of its
own Certification Period activities hereunder.

5.       MARKETING PERIOD.

         5.1 TERM OF MARKETING PERIOD. The Marketing Period shall extend from
the Approval Date until fifteen (15) years thereafter, unless this Agreement is
terminated earlier pursuant to Article 11. The Marketing Period may be renewed
by agreement of the parties for one (1) or more additional terms of five (5)
years each, provided that such agreement is reached at least one hundred eighty
(180) days prior to the expiration of this Agreement or any such additional
term.

         5.2 REASONABLE COMMERCIAL EFFORTS BY HORIZON. Subject to the granting
of all necessary governmental approvals or concurrences to sell the Designated
Product, Horizon hereby agrees to market, promote and sell the Designated
Product throughout the Territory. Each party understands and agrees that the
other does not warrant or commit that the Designated Product will be
successfully marketed, and neither party shall have any liability or
responsibility to the other or to third parties for any such failure of the
development process hereunder, except to the extent such failure results from
said party's intentional misconduct, gross negligence, or material breach of its
duties or obligations as set forth herein.

         5.3 AMOUNT OF ROYALTIES. Horizon hereby agrees to pay to Penwest
royalties on Net Sales made during the Marketing Period ("Royalties"), as
follows:

                                      -10-
<PAGE>   11

                                          [***]-CONFIDENTIAL TREATMENT REQUESTED

                  5.3.1 [***] of Net Sales on all Net Sales until cumulative Net
Sales of [***] U.S. dollars (US$[***]) have been attained;

                  5.3.2 [***] of Net Sales on all Net Sales after cumulative Net
Sales of [***] U.S. dollars (US$[***]) have been attained until cumulative Net
Sales of [***] US. dollars (US$[***]) have been attained; and

                  5.3.3 [***] of Net Sales on all Net Sales after Net Sales of
[***] U.S. dollars (US$[***]) have been attained.

Such Royalties shall be reduced by [***] (e.g. a [***] Royalty would become a
[***] Royalty) with respect to Net Sales of a Designated Product as to which (a)
no license to Penwest Patents or to patent applications or patents included in
the Joint Developments or TIMERx Improvements hereunder is applicable to the
manufacture, sale or use of such Designated Product, or (b) a license to a
patent application included in the Penwest Patents, Joint Developments or TIMERx
Improvements is applicable to the manufacture, sale or use of such Designated
Product, but no patent has yet issued thereon; provided, however, that, with
respect to Section 5.3.3(b), (i) as of the date of issue of any such patent, the
unreduced Royalty shall become payable on all subsequent Net Sales of such
Designated Product and (ii) within ten (10) days following such date, Horizon
shall pay to Penwest an amount equal to the unreduced Royalty that would have
been payable on Net Sales of such Designated Product up until such date less the
total amount of Royalties already paid on such sales.

         5.4 PAYMENT OF ROYALTIES. All Royalties payable pursuant to this
Agreement shall be due quarterly within sixty (60) days following the end of
each calendar quarter for Net Sales in such calendar quarter. Each such payment
shall be accompanied by a statement of Net Sales for the quarter and the
calculation of Royalties payable hereunder. All Royalties and all other amounts
which are overdue under this Agreement shall bear interest at the rate of one
and one-half percent (1 1/2%) per month from the date due through the date of
payment. Horizon shall keep and shall cause its Affiliates and its and their
sublicensees to keep complete, true and accurate records for the purpose of
showing the derivation of all Royalties payable to Penwest under this Agreement.
Penwest's duly accredited representatives (which representatives are approved
for such purpose by Horizon, which approval shall not be unreasonably withheld
nor shall it be revocable by Horizon following the start of any inspection
hereunder) shall have the right to inspect, copy, and audit such records at any
time during reasonable business hours upon reasonable prior notice to Horizon or
any of its Affiliates or sublicensees, respectively, but such right shall not be
exercised more often than once annually (it being understood that a single
exercise of such right may include a series of related or continuing
inspections, copying and audits). Any such audit shall be at the expense of
Penwest, unless the audit reveals that, with respect to the period under audit,
less than ninety-five percent (95%) of the Royalties due to Penwest hereunder
have been reported, in which event Horizon shall pay or reimburse Penwest for
the reasonable expenses of such audit, in addition to Penwest's other remedies
for such underpayment. In the event that any such audit reveals that, with
respect to the period under audit, Horizon has paid to Penwest Royalties in
excess of those due hereunder, Horizon shall be entitled to offset the full
amount of such excess payment against future Royalties due to Penwest.

         5.5 MARKETING PERIOD MILESTONES. Horizon also agrees to pay Penwest the
following non-refundable, non-creditable milestone payments:

                  5.5.1 within [***] days following the first commercial sale of
the Designated Product, [***] U.S. dollars (US$[***]); and

                                      -11-
<PAGE>   12

                                          [***]-CONFIDENTIAL TREATMENT REQUESTED

                  5.5.2 [***] following the first commercial sale of the
Designated Product, [***] U.S. dollars (US$[***]).

         5.6 FORM OF PAYMENT. All monies due hereunder shall be paid in United
States Dollars to Penwest in Patterson, New York, USA. Said payment may be made
at Horizon's option by check or wire transfer.

6.       SUPPLY OF FORMULATED TIMERX.

         6.1 SUPPLY AND REQUIREMENTS OF FORMULATED TIMERX. During the term of
this Agreement, Penwest shall supply Horizon and its Affiliates and
sublicensees, in accordance with the terms set forth in Section 6.2, with
sufficient quantities of Formulated TIMERx to meet their reasonable requirements
for TIMERx, and Horizon shall purchase, all of its requirements, and shall
ensure that its Affiliates and sublicensees purchase all of their requirements,
for controlled-release agents for [***] products that are essentially equivalent
to the Designated Product in the form of Formulated TIMERx from Penwest.

         6.2 PRICE OF TIMERX. The price for all Formulated TIMERx sold hereunder
shall equal the Unit Price multiplied by the number of kilograms of Formulated
TIMERx purchased; provided, however, that the price for the first [***] ([***])
kilograms of Formulated TIMERx sold during the Development Period and/or the
Certification Period shall be [***] U.S. dollars (US$[***]) multiplied by the
number of kilograms of Formulated TIMERx purchased. All sales of Formulated
TIMERx hereunder shall be F.O.B. Patterson, New York, and Horizon shall bear all
transportation, insurance, taxes, duties, and other costs and risks of loss,
spoilage and damage associated with the shipping and delivery of Formulated
TIMERx to Horizon or its Affiliates or sublicensees. Horizon shall pay for all
Formulated TIMERx purchased from Penwest hereunder within thirty (30) days after
receipt by Horizon or any of its Affiliates or sublicensees of an invoice and
the Formulated TIMERx shipped by Penwest.

         6.3 CHANGES TO PENWEST DMF. Penwest warrants that it will not change or
modify its DMF, the Specifications, or its method of manufacture for Formulated
TIMERx without prior written consent from Horizon, which consent shall not be
unreasonably withheld.

         6.4 QUALITY CONTROL. Penwest shall perform quality control tests with
respect to each lot or batch of Formulated TIMERx as required by the FDA as set
forth in the DMF, such testing to be at the expense of (a) Penwest to the extent
such testing pertains to TIMERx or Formulated TIMERx and (b) Horizon to the
extent such testing pertains to [***]. In addition, Penwest may perform such
other tests as Penwest deems necessary in accordance with its applicable
policies. No other or special tests by Penwest with respect to the raw materials
or Formulated TIMERx will be required during the License Term, unless and to the
extent that Horizon establishes that any such other or special tests are
required in order to obtain or maintain FDA approval to market the Designated
Product in the Territory, in which case any such other or special tests that are
to be performed by Penwest shall be agreed to by Penwest, such testing to be at
the expense of (a) Penwest to the extent such testing pertains to TIMERx or
Formulated TIMERx and (b) Horizon to the extent such testing pertains to [***].
Penwest shall, promptly upon completion of any such other or special tests,
deliver to Horizon a copy of the results of such other or special tests. Each
shipment of the Formulated TIMERx shall:

                  6.4.1 be accompanied by a Certificate of Analysis and a
Certificate of Origin;

                  6.4.2    meet all present applicable FDA requirements and the
Specifications; and

                                      -12-
<PAGE>   13

                  6.4.3 be manufactured, packaged, stored and shipped in
conformance with the Specifications and current Good Manufacturing Practices or
other relevant regulations and requirements promulgated by the FDA and
applicable to Formulated TIMERx.

         6.5 NON-ACCEPTANCE OF FORMULATED TIMERX BY HORIZON. Within a reasonable
period but not more than thirty (30) days after receipt, Horizon shall analyze
each shipment of the Formulated TIMERx. If Horizon considers any such shipment
not to conform to the Specifications, Horizon shall notify Penwest immediately
and provide Penwest with the relevant analysis. If Penwest does not agree, the
parties shall submit such disagreement to the arbitration of one mutually
accepted neutral analytical laboratory. The cost of the neutral analytical
laboratory shall be borne by the party whose testing results are determined to
have been in error. If Penwest or the neutral analytical laboratory agrees with
Horizon, Penwest shall not have any obligation to Horizon other than to
accomplish the following:

              i)            at its own expense accept return of any shipment not
                            accepted or reimburse Horizon for the cost of
                            disposal or destruction, at Horizon's option; and

              ii)           use commercially reasonable efforts to replace the
                            non-conforming shipment with conforming Formulated
                            TIMERx.

         6.6 HORIZON ACCESS TO PENWEST FACILITIES. Horizon shall have the right
to enter into Penwest's manufacturing facilities and the manufacturing
facilities of its Affiliates and sublicensees, of any, at times agreed by the
parties and/or to take other appropriate methods to check the quality of the
Formulated TIMERx manufactured or offered by Penwest and its Affiliates and
sublicensees, of any, from time to time during the term of this Agreement after
reasonable prior notice to Penwest and its Affiliates and sublicensees, if any.

         6.7 FORECASTING OF ORDERS BY HORIZON. Throughout the term of this
Agreement, Horizon shall deliver to Penwest, and shall ensure that its
Affiliates and sublicensees, if any, deliver to Penwest, a firm written order
stating their requirements for Formulated TIMERx for each calendar quarter to be
used for production of the Designated Product for commercial use or sale (a
"Firm Order") no less than ninety (90) days in advance of each required delivery
date during such calendar quarter (each a "Firm Order Quarter"). Horizon shall
be responsible for purchasing from Penwest one hundred percent (100%) of the
quantity of Formulated TIMERx specified in each such Firm Order. The first Firm
Order shall be submitted immediately following the reasonable determination by
Horizon that the NDA for the Designated Product will be approved by the FDA and
shall be accompanied by a written, non-binding estimate of Horizon's
requirements for Formulated TIMERx to be used for production of the Designated
Product for commercial use or sale (an "Estimated Order") during the next three
(3) calendar quarters following the first Firm Order Quarter. On or before the
first day of (a) the calendar quarter following the first Firm Order Quarter and
(b) each Firm Order Quarter thereafter, Horizon shall deliver to Penwest an
Estimated Order covering the three (3) calendar quarters following each such
Firm Order Quarter.

         6.8 ADHERENCE TO ESTIMATED ORDERS. Unless the parties otherwise agree
in writing, Penwest shall not be obligated to supply Horizon with quantities of
Formulated TIMERx during any calendar quarter in excess of one hundred forty
percent (140%) of the quantity estimated in Horizon's most recent Estimated
Order applicable to that quarter. Horizon shall be responsible for purchasing
from Penwest in each calendar quarter at least seventy-five percent (75%) of the
quantity estimated in Horizon's most recent Estimated Order applicable to that
quarter.

         6.9 PRODUCT SAFETY; GOVERNMENT INSPECTIONS. Each party shall promptly
notify the other of any fact, circumstance, condition or knowledge dealing with
TIMERx, Formulated TIMERx or the

                                      -13-
<PAGE>   14

Designated Product of which the party becomes aware that bears upon the safety
or efficacy of TIMERx, Formulated TIMERx or the Designated Product. Each party
shall immediately notify the other of any inspection or audit relating to
TIMERx, Formulated TIMERx or the Designated Product by any governmental
regulatory authority in the Territory. If a representative of the governmental
authority takes samples in connection with such audit or inspection, the parties
shall immediately provide each other, as appropriate, with samples from the same
batch. The party in receipt of such notice shall provide the other party, within
seventy-two (72) hours, with copies of all relevant documents, including but not
limited to FDA Forms 482, 483, warning letters and other correspondence and
notifications as such other party may reasonably request. Penwest and Horizon
agree to cooperate with each other during any inspection, investigation or other
inquiry by the FDA or other governmental entity, including but not limited to
providing information and/or documentation, as requested by the FDA or other
governmental entity. To the extent permissible, Penwest and Horizon also agree
to discuss any responses to observations or notifications received and to give
the other party an opportunity to comment on any proposed response before it is
made. In the event of disagreement concerning the content or form of such
response, Horizon shall be responsible for deciding the appropriate form and
content of any response with respect to any of its cited activities and Penwest
shall be responsible for deciding the appropriate form and content of any
response with respect to any of its cited activities. Each party shall inform
the other of all comments and conclusions received from the governmental
authority.

         6.10 PACKAGING OF DESIGNATED PRODUCT; USE OF PENWEST TRADEMARK(S).
Horizon shall manufacture and package the Designated Product in accordance with
all applicable laws and regulations in the Territory. Provided that the Penwest
Trademark(s) remain registered in the Territory, and that Penwest undertakes
reasonable efforts to protect and defend the same in the Territory, Horizon
agrees, upon and only upon Penwest's request, to market the Designated Product
in the Territory in conjunction with the appropriate Penwest Trademark(s). In
the event that Penwest so requests, the parties agree to the following:

                  6.10.1 Horizon acknowledges that all Penwest Trademark(s) and
all rights therein or registrations thereof, worldwide, shall belong exclusively
to Penwest, and Penwest shall use all reasonable efforts to obtain and maintain
registrations for the Penwest Trademark(s) in the Territory. All use of the
Penwest Trademark(s) as contemplated in this Agreement by Horizon shall accrue
to the benefit of Penwest. Neither Horizon nor its Affiliates or sublicensees
shall (a) make use of any of the Penwest Trademark(s) except to identify and
promote the Designated Product as contemplated hereunder for sale in the
Territory, or (b) continue using the Penwest Trademark(s) after termination or
expiration of this Agreement, nor after the removal or alteration of any such
Penwest Trademark(s) from Exhibit D, except to complete sale of reasonable
quantities of inventory of the Designated Product on hand at the time of
termination or expiration, or at the time of such removal or alteration.

                  6.10.2 Horizon shall cooperate with Penwest, at Penwest's
request and at Penwest's expense, to protect the interest of Penwest in the
Penwest Trademark(s), and shall neither attempt to register nor authorize others
to register the Penwest Trademark(s) without the prior written consent of
Penwest in each instance.

                  6.10.3 Horizon shall use, and shall ensure that its Affiliates
and sublicensees, if any, use, all appropriate notices of trademark status of
the Penwest Trademark(s), including the "(TM)" designation (or the (R) symbol
for registered marks), in all labeling and promotional materials and shall
otherwise conform with, and shall ensure that its Affiliates and sublicensees,
if any, conform with, all policies and notices of Penwest's rights in the
Penwest Trademark(s) and for the protection of the

                                      -14-
<PAGE>   15

Penwest Trademark(s), including without limitation the inclusion of an
appropriate footnote acknowledging the use of the Penwest Trademark(s) under
license.

                  6.10.4 Representative samples of the Designated Product and
any advertising, promotional materials or packaging related thereto shall be
provided by Horizon to Penwest, at Horizon's expense, at least thirty (30) days
prior to the first use or sale thereof, quarterly thereafter and at other times
upon the reasonable written request of Penwest. So long as Horizon is using the
Penwest Trademark(s) in the Territory, Penwest shall have the right to enter
into Horizon's manufacturing facilities and the manufacturing facilities of its
Affiliates and sublicensees, if any, at times agreed by the parties and/or to
take other appropriate methods to check the quality of the Designated Product
manufactured or offered by Horizon and its Affiliates and sublicensees, if any,
from time to time during the term of this Agreement after reasonable prior
notice to Horizon and its Affiliates and sublicensees, if any. If at any time or
times Penwest determines that the quality of the Designated Product manufactured
or offered by Horizon and its Affiliates and sublicensees, if any, or the
packaging or promotional materials therefor, does not comply with Penwest
standards as communicated in writing from time to time to Horizon and its
Affiliates and sublicensees, if any, Penwest (a) shall so notify Horizon and its
Affiliates and sublicensees, if any, in writing and (b) if Horizon and/or its
Affiliates and sublicensees, as the case may be, has not cured such
non-compliance within sixty (60) days following such notice, shall have the
right (as its only remedy as to trademark matters) to suspend or prohibit the
use of the Penwest Trademark(s), immediately upon written notice to Horizon and
its Affiliates and sublicensees; provided, however, that Penwest need not give
such opportunity to cure any non-compliance that has been the subject of more
than two such notices on prior occasions during the preceding twelve (12)
months.

7.       OWNERSHIP OF TECHNOLOGY AND INTELLECTUAL PROPERTY.

         7.1 OWNERSHIP OF INTELLECTUAL PROPERTY. Horizon agrees to assign and
ensure that each of its Affiliates and sublicensees, if applicable, assigns its
rights in and to any and all TIMERx Improvements to Penwest. All right, title,
and interest in and to any and all Joint Developments shall be owned jointly by
Horizon and Penwest, and, except as specifically provided in this Agreement,
each party shall have the full right to practice and license such Joint
Developments, without obligation to obtain the approval of or to make payment of
any kind to the other party in respect thereof. Horizon shall have the right to
obtain, at its sole expense, and shall solely own any trademarks relating to the
Designated Product, subject to the approval of Penwest, which approval shall not
be unreasonably withheld. Neither party makes any grant of rights by
implication.

         7.2 PROSECUTION AND MAINTENANCE OF INTELLECTUAL PROPERTY. Penwest shall
be responsible for the filing and prosecution of any and all patent applications
with respect, in whole or in part, to its own intellectual property and for the
maintenance of any available patent protection with respect thereto; provided,
however, that Penwest does not represent that any such patent protection will be
available or continuous hereunder.

         7.3 MARKING OF PATENTED PRODUCTS. Horizon agrees to mark and to have
marked by its Affiliates and sublicensees (if any) every Designated Product
manufactured, used or sold by it or its Affiliates or sublicensees in the
Territory, in accordance with the laws of the United States relating to the
marking of patented articles with notices of patent.

8.       CONFIDENTIALITY

         8.1 NON-DISCLOSURE OF CONFIDENTIAL INFORMATION. In the course of
performance under this Agreement, a party may disclose to the other Confidential
Information belonging to such party in writing,

                                      -15-
<PAGE>   16

orally or by demonstration or sample, which information is marked or stated in
writing at or within thirty (30) days after its disclosure to be "confidential"
or "trade secret" information. All such Confidential Information of a party
shall be maintained in confidence by the other and shall not be used by the
other party for any purpose except as authorized hereunder. Each party shall
exercise, and shall cause its Affiliates, sublicensees, consultants, agents and
employees to exercise, a reasonable degree of care and at least the same degree
of care as it uses to protect its own confidential information of similar nature
to preserve the confidentiality of such information of the other party. Each
party shall safeguard such information against disclosure to third parties,
including without limitation employees and persons working or consulting for
such party that do not have an established, current need to know such
information for purposes authorized under this Agreement. This obligation of
confidentiality does not apply to information and material that:

                  8.1.1 were properly in the possession of the receiving party,
without any restriction on use or disclosure, prior to receipt from the other
party;

                  8.1.2 are at the time of disclosure hereunder in the public
domain by public use, publication, or general knowledge;

                  8.1.3 become general or public knowledge through no fault of
the receiving party or its Affiliates or sublicensees following disclosure
hereunder;

                  8.1.4 are properly obtained by the receiving party from a
third party not under a confidentiality obligation to the disclosing party
hereto;

                  8.1.5 consist merely of an idea or conception for the
combination of one or more active drug ingredients with a controlled-release
agent such as TIMERx; or

                  8.1.6 are required to be disclosed by order of any court or
governmental authority.

         8.2 NON-DISCLOSURE OF TERMS OF OR WORK UNDER AGREEMENT. Neither party
shall make any disclosure, public announcement or other publication regarding
this Agreement (whether as to the existence, conditions or terms thereof) or the
development work or projects performed hereunder or the results thereof,
including but not limited to the results of any clinical trial involving the
Designated Product, without the prior, written consent of the other party, which
consent shall not be unreasonably withheld; provided, however, that either party
may disclose the terms and conditions of this Agreement (a) as required, in the
opinion of counsel to the disclosing party, by any court, administrative agency,
or other governmental body, after making all reasonable efforts to protect the
confidentiality thereof and providing notice to the disclosing party, (b) as
otherwise required by law, (c) in confidence, to legal counsel, accountants,
banks, and financing sources and their advisors, (d) in confidence, in
connection with the enforcement of this Agreement or rights under this
Agreement, or (e) in confidence, in connection with a merger or acquisition or
proposed merger or proposed acquisition. Each party shall ensure that its
Affiliates, sublicensees, consultants, agents and employees comply with the
provisions of this Section 8.2.

9.       INFRINGEMENT.

         9.1 NOTICE AND PREVENTION OF INFRINGEMENT. Penwest shall (a) promptly
inform Horizon of any suspected infringement of any of the Penwest Patents or
Penwest Trademark(s) or the infringement or misappropriation of any of the
Penwest Technology, the Joint Developments or TIMERx Improvements by a third
party, to the extent such infringement involves the manufacture, use or sale of
the Designated Product in the Territory ("Covered Infringement") and (b)
consistent with its policies as to

                                      -16-
<PAGE>   17

its TIMERx patent and trade secret portfolio generally, exert reasonable efforts
to monitor and to attempt to stop any Covered Infringement. Horizon shall
promptly inform Penwest of any suspected infringement of any of the Penwest
Patents or Penwest Trademark(s) or infringement or misappropriation of any of
the Penwest Technology, the Joint Developments or TIMERx Improvements, whether
or not the same involves a Covered Infringement.

         9.2 PENWEST ACTION AGAINST INFRINGERS. If the suspected infringement or
misappropriation does not involve a Covered Infringement, Penwest may take, or
refrain from taking, any action it chooses, with written notice to Horizon, and
Horizon shall have no right to take any action with respect to such suspected
infringement or misappropriation, nor to any recoveries with respect thereto. If
the suspected infringement or misappropriation involves a Covered Infringement,
Penwest shall, within thirty (30) days of the first notice referred to in
Section 9.1, inform Horizon whether or not Penwest intends to institute suit
against such third party with respect to a Covered Infringement. Horizon shall
not take any steps toward instituting suit against any third party involving a
Covered Infringement until Penwest has informed Horizon of its intention
pursuant to the previous sentence, and then only in accordance with the terms
set forth in Sections 9.2.2 and 9.3.

                  9.2.1 If Penwest notifies Horizon that it intends to institute
suit against a third party with respect to a Covered Infringement, and Horizon
does not agree to join in such suit as provided in Section 9.2.2, Penwest may
bring such suit on its own and shall in such event bear all costs of, and shall
exercise all control over, such suit Horizon agrees to, at its expense, provide
any assistance to and cooperate as reasonably necessary with Penwest to
institute and/or maintain any such suit with respect to any Covered
Infringement. Recoveries, if any, whether by judgment, award, decree or
settlement, shall belong solely to Penwest.

                  9.2.2 If Penwest notifies Horizon that it intends to institute
suit against such third party with respect to a Covered Infringement, and
Horizon notifies Penwest within thirty (30) days after receipt of such notice
that Horizon desires to institute suit jointly, the suit shall be brought
jointly in the names of both parties and all costs thereof shall be borne
equally. Recoveries, if any, whether by judgment, award, decree or settlement,
shall, after the reimbursement of each of Penwest and Horizon for its share of
the joint costs in such action, be shared between Penwest and Horizon equally;
provided, however, that any portion of such net recoveries that constitutes the
equivalent of, or damages or payments in lieu of, defendant's net sales shall
not be shared equally, but shall belong to Horizon and be added to Horizon's Net
Sales for the purpose of determining Royalties payable to Penwest.

10.      REPRESENTATIONS, WARRANTIES AND INDEMNITIES.

         10.1 AUTHORITY TO ENTER INTO AGREEMENT; VALIDITY OF PATENTS; DEBARMENT.
Each party represents and warrants to the other that, to the best of its current
knowledge, it has the full right and authority to enter into this Agreement and
to grant the licenses granted herein. Each party believes, to the best of its
current knowledge, that any existing patents licensed by it to the other party
under this Agreement are valid. Each party represents and warrants to the other
that neither it nor any of its officers, directors, or employees performing
services under this Agreement has been debarred, or convicted of a crime which
could lead to debarment, under the Generic Drug Enforcement Act of 1992, 21
United States Code ss.ss.306(a) and (b). In the event that either party, or any
of its officers, directors, or employees performing services under this
Agreement, (a) becomes debarred or receives notice of action or threat of action
with respect to its debarment or (b) becomes the object of any investigation or
subject of any report regarding such party, or any of its officers, directors,
or employees performing services under this Agreement, in connection with any
activity that could result in debarment or suspension or refusal of

                                      -17-
<PAGE>   18

approval, including without limitation any inspection report, warning letter,
notice of opportunity for hearing in a case of debarment, or any other Justice
Department, FDA or other federal or state government inquiry or action bearing
on potentially illegal activities, such party shall notify the other party
immediately.

         10.2 PENWEST WARRANTIES TO TIMERX. Penwest represents and warrants that
any Formulated TIMERx supplied by it to Horizon hereunder for use in the
Designated Product, at the point of delivery (a) has been manufactured in
accordance with cGMP, (b) will conform to the Specifications, and (c) to the
best of Penwest's current knowledge, will not infringe upon an article patent of
any third party.

PENWEST MAKES NO REPRESENTATIONS OR WARRANTIES AS TO ANY TIMERX OR FORMULATED
TIMERX SUPPLIED BY IT TO HORIZON EXCEPT AS ARE EXPLICITLY STATED HEREIN.

         10.3 GOVERNMENT LICENSES, PERMITS AND AUTHORIZATIONS. Each party
represents and warrants to the other party that it has obtained and will at all
times during the term of this Agreement, hold and comply with all licenses,
permits and authorizations necessary to perform this Agreement and to test,
manufacture, market, export, and import the products and assistance to be
provided by it hereunder, as now or hereafter required under any applicable
statutes, laws, ordinances, rules and regulations of the United States and any
applicable foreign, state, and local governments and governmental entities.

         10.4 GOVERNMENT REGULATORY REQUIREMENTS. Horizon warrants that any
Designated Product manufactured, marketed or distributed by Horizon or its
Affiliates or sublicensees shall meet and be manufactured, packaged, labeled,
sold, and promoted in accordance with all applicable regulatory requirements
within the Territory.

         10.5 INDEMNIFICATION BY PENWEST AGAINST INFRINGEMENT CLAIMS. Penwest
shall indemnify, defend and hold Horizon and its Affiliates and sublicensees
harmless from any claim, action or damages arising out of any alleged
infringement by reason of the manufacture, use, sale or distribution by Horizon
of the Designated Product to the extent such infringement would apply as well to
the manufacture, sale or distribution of TIMERx alone. If Horizon or its
Affiliate or sublicensee, by reason of its manufacture, sale or distribution of
the Designated Product, is accused of infringing the patent of a third party,
and such claim of infringement, as framed by the claimant, would apply as well
to the manufacture, sale or distribution of TIMERx alone, Horizon shall
immediately so notify Penwest and provide Penwest with all available
information, and the parties shall consult reasonably as to the proper course of
action. If Penwest and Horizon jointly determine that such claim is likely to
prevail, or if an arbitrator hereunder or a court of competent jurisdiction so
determines, Horizon shall be entitled to offset against any Royalties payable to
Penwest hereunder the full amount of any third party royalties for which Horizon
or its Affiliate or sublicensee becomes liable. For any given year following the
Approval Date, such offset shall not reduce the Royalties payable to Penwest to
less than (a) if such Royalties have not been reduced pursuant to Section 5.3,
fifty percent (50%) of the Royalty amount otherwise due Penwest absent such
offset, or (b) if such Royalties have been reduced pursuant to Section 5.3,
twenty-five percent (25%), of the Royalty amount otherwise due Penwest absent
such offset and reduction; provided, however, that Horizon may carry forward any
unutilized portion of such offset to future years.

         10.6 INDEMNIFICATION BY PENWEST AGAINST OTHER THIRD PARTY CLAIMS.
Penwest shall indemnify, defend and hold Horizon and its Affiliates and
sublicensees harmless from any and all third-

                                      -18-
<PAGE>   19

party claims (other than infringement claims) to the extent arising from, in
connection with, based upon, by reason of, or relating in any way to:

                  10.6.1 Penwest's contributions to the formulation or
development of the Formulated TIMERx and the Specifications therefor hereunder;

                  10.6.2 any failure of the Formulated TMERx supplied by Penwest
to Horizon hereunder for use in the Designated Product to conform to the
Specifications; or

                  10.6.3 any failure of Penwest to comply with its obligation
under Section 6.9 to notify Horizon of any information coming into Penwest's
possession and bearing on the safety of TIMERx or the Designated Product;

and, with respect to Sections 10.6.1, 10.6.2 and 10.6.3, not arising from any
other aspect of the Designated Product or its formulation, development, supply,
production, manufacture, sale, delivery, distribution or use, or from any act or
omission of Horizon with respect to the Formulated TIMERx following its delivery
to Horizon hereunder.

         10.7 INDEMNIFICATION BY HORIZON AGAINST OTHER THIRD PARTY CLAIMS.
Horizon shall indemnify, defend and hold Penwest harmless from any and all
third-party claims to the extent arising from, in connection with, based upon,
by reason of, or relating in any way to, the formulation, development, supply,
production, manufacture, sale, delivery, distribution or use of the Designated
Product, except for any matters which are covered by Penwest's indemnities under
Sections 10.5 and 10.6.

         10.8 INDEMNIFICATION BY HORIZON AGAINST INFRINGEMENT CLAIMS. Horizon
shall indemnify, defend and hold Penwest harmless from and against any patent
claims or litigation (and all damages and expenses associated therewith,
including without limitation reasonable attorneys fees and other costs of
defense and of the preparation of a defense, at all stages of proceedings) based
on any feature of the Designated Product or its formulation, independent of the
TIMERx component by itself. Penwest shall cooperate and assist Horizon
reasonably with the defense of any such claims or litigation. It is understood
that neither Horizon nor Penwest shall have the right to force the other into
any settlement or compromise of any such litigation, nor to dictate the terms
thereof.

         10.9 INDEMNIFICATION DISCLAIMER. Notwithstanding anything to the
contrary set forth elsewhere herein, neither Horizon nor Penwest shall be
obligated to indemnify the other party for claims or liabilities to the extent
arising from such other party's, or its Affiliates', sublicensees' or assigns',
gross negligence, intentional misconduct, or material breach of its duties,
obligations, warranties or representations set forth herein.

         10.10 INDEMNIFIED PARTIES; NOTICE AND DEFENSE OF THIRD PARTY CLAIMS.
Whenever indemnification is provided for a party under this Agreement with
respect to any claim or action, such right of indemnification shall extend also
to the indemnified party's Affiliates, officers, directors, shareholders,
successors, assigns, agents, employees, and insurers to the extent the same
become subject to such claim or action in such capacity. The party seeking
indemnification shall provide the indemnifying party with written notice of such
claim or action within ten (10) days of its receipt thereof and shall afford the
indemnifying party the right to control the defense and settlement of such claim
or action. The party seeking indemnification shall provide reasonable assistance
to the indemnifying party in the defense of such claim or action. If the
defendants in any such action include both Horizon and Penwest and either party
concludes that there may be legal defenses available to it which are different

                                      -19-
<PAGE>   20

from, additional to, or inconsistent with, those available to the other, that
party shall have the right to select separate counsel to participate in the
defense of such action on its behalf, and such party shall thereafter bear the
cost and expense of such separate defense. Should the indemnifying party
determine not to defend such claim or action, the other party shall have the
right to maintain the defense of such claim or action and the indemnifying party
agrees to provide reasonable assistance to it in the defense of such claim or
action. Neither party to this Agreement shall settle or defend such claim or
action in a way that prejudices or adversely affects the other party to this
Agreement without the prior approval of such other party (which approval shall
not be unreasonably withheld).

         10.11 DISPUTES CONCERNING INDEMNIFICATION. Any dispute concerning
indemnification shall be determined by arbitration in accordance with Section
12.10 of this Agreement.

         10.12 LIMITATION OF WARRANTIES. THE FOREGOING WARRANTIES ARE IN LIEU OF
ALL OTHER WARRANTIES, EXPRESS, IMPLIED OR ARISING BY LAW, INCLUDING WITHOUT
LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A
PARTICULAR PURPOSE. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A
REPRESENTATION OR WARRANTY (A) BY PENWEST AS TO THE PATENTABILITY, VALIDITY
(EXCEPT AS STATED IN SECTION 10.1), OR SCOPE OF ANY PENWEST PATENTS, PENWEST
TECHNOLOGY, PENWEST'S CONFIDENTIAL INFORMATION, JOINT DEVELOPMENTS, OR PENWEST
TEST AND REGULATORY DATA; OR (B) BY HORIZON AS TO THE PATENTABILITY, VALIDITY
(EXCEPT AS STATED IN SECTION 10.1), OR SCOPE OF ANY TIMERX IMPROVEMENTS, JOINT
DEVELOPMENTS, OR HORIZON TEST AND REGULATORY DATA.

         10.13 LIMITATION OF LIABILITY. NOTWITHSTANDING ANYTHING TO THE CONTRARY
CONTAINED HEREIN, NEITHER PARTY SHALL UNDER ANY CIRCUMSTANCES BE LIABLE FOR ANY
THIRD PARTY CLAIMS (OTHER THAN THE INDEMNIFICATIONS STATED IN THIS ARTICLE 10)
OR FOR ANY INCIDENTAL, CONSEQUENTIAL, INDIRECT OR SPECIAL DAMAGES INCLUDING ANY
LOST PROFITS OR SAVINGS, ARISING FROM ANY BREACH OF WARRANTY OR THE PERFORMANCE
OR BREACH OF ANY OTHER PROVISION OF THIS AGREEMENT OR THE USE OR INABILITY TO
USE TIMERx, FORMULATED TIMERx, THE DESIGNATED PRODUCT, PENWEST PATENTS, PENWEST
TECHNOLOGY, PENWEST'S CONFIDENTIAL INFORMATION, JOINT DEVELOPMENTS, PENWEST TEST
AND REGULATORY DATA, TIMERX IMPROVEMENTS, OR HORIZON TEST AND REGULATORY DATA,
EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

                                      -20-
<PAGE>   21

         10.14 INSURANCE COVERAGE. Each party shall, at its own cost and
expense, obtain and maintain from a qualified insurance company comprehensive
general liability and products liability insurance coverage during the term of
this Agreement (and any subsequent period of sale or distribution pursuant to
Section 11.6). Such insurance shall be in an amount no less than one million
U.S. dollars (US$1,000,000) combined single limit for each occurrence for bodily
injury and/or property damage. Each party agrees to provide the other party with
a certificate of insurance evidencing such insurance within thirty (30) days
after the Effective Date and again thereafter from time to time as reasonably
requested by such other party.

11.      TERM AND TERMINATION.

         11.1 TERM. The term of this Agreement shall begin on the Effective Date
and shall, unless extended or earlier terminated as provided herein, continue
until fifteen (15) years following the Approval Date.

         11.2 TERMINATION BY PENWEST. Penwest may at its option terminate this
Agreement upon thirty (30) days' prior written notice to Horizon if:

                  11.2.1 Horizon fails to:

                           11.2.1.1 file an IND for the Designated Product
within twelve (12) months following the Effective Date, unless Horizon's failure
to do so is attributable to Penwest;

                           11.2.1.2 initiate a program of clinical trials for
the Designated Product within three (3) months following successful completion
of preformulation, formulation, dissolution testing and biostudy formulation
finalization with respect to the Designated Product, unless Horizon's failure to
do so is attributable to Penwest;

                           11.2.1.3 complete a program of clinical trials for
the Designated Product within twenty-four (24) months following the initiation
of such program, unless Horizon's failure to do so is attributable to Penwest;

                           11.2.1.4 file an NDA for the Designated Product
within six (6) months following the successful completion of a program of
clinical trials for the Designated Product, unless Horizon's failure to do so is
attributable to Penwest; or

                           11.2.1.5 commercially launch the Designated Product
within two (2) months following approval by the FDA of an NDA for the Designated
Product, unless Horizon's failure to do so is attributable to Penwest; or

                  11.2.2 Horizon fails to meet the relevant Minimum Sales, as
specified in Exhibit G, for any two (2) consecutive years following the Approval
Date, unless (a) the sum of the Minimum Sales for all years since the Approval
Date less the sum of Horizon's Net Sales for such years (the "Sales
Differential") is equal to or less than zero, or (b) if the Sales Differential
is greater than zero Horizon makes, within such thirty (30) day period, an
additional payment to Penwest equal to the product of (i) the Sales Differential
and (ii) the applicable royalty percentage set forth in Section 5.3.

         11.3 TERMINATION BY HORIZON. Horizon shall have the right, at its
option, to terminate this Agreement:

                  11.3.1 at any time prior to the first anniversary of the
Effective Date upon ninety (90) days' prior notice to Penwest, if Horizon,
despite its commercially reasonable efforts, expects to be unable to meet the
Minimum Sales specified in Exhibit G for the first year following the Approval
Date;

                                      -21-
<PAGE>   22

provided, however, that Horizon shall pay Penwest an early termination fee
of five hundred thousand U.S. dollars (US$500,000) at the time of any exercise
of Horizon's option to terminate for this reason; or

                  11.3.2 upon ninety (90) days' prior written notice to Penwest,
if Horizon fails to meet the relevant Minimum Sales, as specified in Exhibit G,
for any two (2) consecutive years following the Approval Date.

         11.4 EXTENSION OF LICENSES. Following any expiration or termination of
this Agreement, other than due to an uncured breach on the part of Penwest (but
subject to Section 11.8), Penwest may request that the license to Penwest under
Section 2.2.2 be extended to include (in addition to their coverage as stated in
such section) making, using and selling the Designated Product in the Territory
and the use of Horizon Test and Regulatory Data for purposes of complying with
governmental requirements with respect to the Designated Product for marketing
or use in the Territory, and otherwise continue to be governed by the terms
stated in such section. In the event of such a request by Penwest, Horizon
agrees to enter into good faith negotiations with Penwest concerning a
reasonable payment to be made by Penwest to Horizon in consideration of such an
extension.

         11.5 TERMINATION DUE TO BREACH. In the event that either party
materially breaches any of the terms, conditions or agreements contained in this
Agreement to be kept, observed or performed by it, then the other party may
terminate this Agreement, at its option, by giving the party who committed the
breach (a) in the case of breach of obligations other than the payment of money,
ninety (90) days' notice in writing, unless the notified party within such
ninety (90) day period shall have cured the breach, and (b) in the case of
breach of an obligation for the payment of money, thirty (30) days' notice in
writing, unless the notified party within such thirty (30) day period shall have
cured the breach, including any required payment of interest on previously
unpaid amounts as set forth herein; provided, however, that:

              11.5.1 no termination of this Agreement under this Section 11.5
shall become effective during the pendency of a good faith dispute between the
parties as to the existence of grounds for such a termination, provided that the
parties are complying with the process in Section 12.10 in good faith in order
to resolve such dispute, and that such termination shall become effective
immediately upon any binding determination that such grounds did exist at the
time the notice of termination was given; and

              11.5.2 if a notice of termination is given pursuant to this
Section 11.5 and it is subsequently determined that grounds for such a notice
did not exist, the giving of such notice shall not itself constitute a
repudiation or default under this Agreement, so long as such notice was given in
the good faith belief that such grounds did exist.

No termination of this Agreement under this Section 11.5 shall impair either
party's right to seek other legal or equitable rights or remedies.

         11.6 DELETION OF INVENTORY FOLLOWING TERMINATION. In the event of any
expiration or termination of this Agreement, Horizon shall be entitled to sell
and distribute reasonable inventories of Designated Product remaining on hand as
of the effective date of such expiration or termination, provided that such
sales and distribution are otherwise in conformance with this Agreement. Horizon
may continue to make, use or sell such Designated Product only until Horizon has
exhausted remaining raw materials in its possession at the time of expiration or
termination of this Agreement. Net Sales of the Designated Product pursuant to
this Section 11.6 shall be subject to the Royalty payment obligations set forth
in Section 5.3.

                                      -22-
<PAGE>   23

         11.7 TERMINATION OR ASSIGNMENT OF SUBLICENSEES. Any sublicenses granted
by Horizon or its Affiliates under this Agreement shall provide for termination
or assignment to Penwest, at the option of Penwest, of Horizon's or its
Affiliate's interest therein upon expiration or termination of this Agreement.

         11.8 SURVIVAL OF TERMS. Horizon's obligations regarding payment of
Royalties accrued as of the date of expiration or termination of this Agreement,
and the provisions of Sections 7.1, 8, 10, 11 and 12 hereof shall survive any
expiration or termination of this Agreement.

         11.9 RETURN OF DATA AND MATERIALS. In the event of any termination or
expiration of this Agreement, (a) Horizon shall return to Penwest all Penwest
data and materials and (b) Penwest shall return to Horizon all Horizon data and
materials, except to the extent such Horizon data and materials are necessary to
permit Penwest to fully exercise its retained rights hereunder.

12.      MISCELLANEOUS.

         12.1 FURTHERANCE OF AGREEMENT. Each of Penwest and Horizon agrees to
duly execute and deliver, or cause to be duly executed and delivered, such
further instruments and cause to be done such further acts and things as are
reasonably within its control and its responsibilities under this Agreement,
including, without limitation, the filing of such additional assignments,
agreements, documents and instruments, that may be necessary or as the other
party hereto may from time to time reasonably request in connection with this
Agreement to carry out more effectively the provisions and purposes of this
Agreement.

         12.2 ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
and supersedes all prior agreements and understandings, both written and oral,
between the parties hereto with respect to the subject matter hereof.

         12.3 ASSIGNMENT. This Agreement shall be binding upon and inure to the
benefit of the parties hereto and their Affiliates, successors and permitted
assigns; provided, however, that except for assignments or delegations to
Affiliates of a party (which shall not release such party from any of its rights
or responsibilities hereunder), or as part of the transfer of all or
substantially all assets to a single buyer or pursuant to a merger, sale of all
or substantially all of such party`s stock or any similar transaction, or as
otherwise specifically permitted hereunder, neither party shall assign or
delegate any of its rights or obligations hereunder at any time without the
prior written consent of the other party hereto, which consent shall not be
unreasonably withheld. Penwest's decision with respect to such consent shall be
based on whether, as of the time of the proposed assignment, the proposed
assignee is a Capable Entity. Penwest shall notify Horizon of such decision
within sixty (60) days following Penwest's receipt from Horizon of any written
proposal concerning assignment of this Agreement. Notwithstanding the foregoing,
Horizon shall have the right to assign or delegate any of its rights or
oblations hereunder to Inpharmakon without the prior written consent of Penwest;
provided, however, that (a) any such assignment or delegation to Inpharmakon
shall be limited to Horizon's rights and obligations hereunder with respect to
the Designated Product for use for the Indication, and (b) six (6) months
following such assignment or delegation, (i) such right shall become ineffective
and (ii) Horizon shall terminate any such assignment or delegation, unless
Inpharmakon has entered into an agreement with a Capable Entity for development
of the Designated Product. Horizon shall reimburse Penwest for reasonable
attorneys' fees incurred by Penwest in connection with such assignment to
Inpharmakon, whether or not such assignment remains effective and continues
beyond the end of such six (6) month period. In no event shall Horizon assign
rights hereunder unless the proposed assignee agrees to assume those of
Horizon's

                                      -23-
<PAGE>   24

obligations hereunder that are relevant to the scope of the proposed
assignment, including but not limited to Horizon's due diligence and
confidentiality obligations and Horizon's obligation to pay milestones. Out of
any Assignment-Related Compensation received by Horizon from any third party,
Horizon shall reimburse Penwest for Penwest's costs incurred in connection with
the development of the Designated Product, except to the extent such costs have
already been reimbursed by Horizon through the payment of milestones hereunder.
For the purposes of this Section 12.3, "Assignment-Related Compensation" shall
mean any payments of any kind whatsoever received by Horizon from a third party
in consideration for, or otherwise in connection with, the assignment of all or
any part of Horizon's rights under this Agreement. In the event that this
Agreement is assigned as part of the sale of all or substantially all of the
assets of Horizon, or Horizon is acquired pursuant to a merger, sale of stock or
similar transaction, then, out of the proceeds from such transaction, Horizon
shall reimburse Penwest for Penwest's costs incurred in connection with the
development of the Designated Product, except to the extent such costs have
already been reimbursed by Horizon through the payment of milestones hereunder.

         12.4 NOTICES. All notices, requests or other communication provided for
or permitted hereunder shall be given in writing and shall be hand delivered or
sent by facsimile, reputable courier or by registered or certified mail, postage
prepaid, return receipt requested, to the address set forth on the signature
page of this Agreement, or to such other address as either party may inform the
other of in writing. Notices will be deemed delivered on the earliest of
transmission by facsimile, actual receipt or three days after mailing as set
forth herein.

         12.5 MODIFICATIONS; WAIVERS. No change, modification, extension,
termination or waiver of any obligation, term or provision contained herein
shall be valid or enforceable unless same is reduced to writing and signed by a
duly authorized representative of each of the parties to be bound hereby. No
waiver of any right in any one instance shall constitute a waiver of that right
or of any other right in other instances under this Agreement.

         12.6 SEVERABILITY. If any provision of this Agreement shall be held
invalid, illegal or unenforceable, such provision shall be enforced to the
maximum extent permitted by law and the parties' fundamental intentions
hereunder, and the remaining provisions shall not be affected or impaired.

         12.7 INDEPENDENT CONTRACTORS. Nothing herein contained shall constitute
this a joint venture agreement or constitute either party as the partner,
principal or agent of the other, this being an Agreement between independent
contracting entities. Neither party shall have the authority to bind the other
in any respect whatsoever. Except as provided herein, nothing contained in this
Agreement shall be construed as conferring any right on either party to use any
name, trade name, trademark or other designation of the other party hereto,
unless the express, written permission of such other party has been obtained.

         12.8 FORCE MAJEURE. In the event that either party hereto is prevented
from carrying out its obligations under this Agreement by events beyond its
reasonable control, including without limitation acts or omissions of the other
party, acts of God or government, natural disasters or storms, fire, political
strife, labor disputes, failure or delay of transportation, default by suppliers
or unavailability of parts, then such party's performance of its obligations
hereunder shall be excused during the period of such event and for a reasonable
period of recovery thereafter, and the time for performance of such obligations
shall be automatically extended for a period of time equal to the duration of
such event or events.

         12.9 GOVERNING LAW. This Agreement shall be governed by, and construed
and enforced in accordance with, the laws of the State of New York without
regard to its conflict of laws rules.

                                      -24-
<PAGE>   25

         12.10 DISPUTE RESOLUTION. Any dispute, controversy, or claim arising
out of or relating to this Agreement or to a breach thereof, including its
interpretation, performance, or termination, other than any dispute, controversy
or claim concerning patent infringement, validity or enforceability, shall be
finally resolved by arbitration. The arbitration shall be conducted by three (3)
arbitrators, one to be appointed by the party initiating the proceeding within
ten (10) days of filing its claim, one to be appointed within thirty (30) days
thereafter by the other party, and the third being nominated by the two
arbitrators so selected within thirty days thereafter or, if they cannot agree
on a third arbitrator, by the President of the American Arbitration Association.
The arbitration shall be conducted in accordance with the Commercial Arbitration
Rules of the American Arbitration Association, which shall administer the
arbitration, and the laws of the State of New York. The arbitration, including
the rendering of the award, shall take place in New York, New York. The decision
of the arbitrators shall be binding upon the parties to this Agreement, and the
expense of the arbitration (including without limitation the award of the
attorneys' fees to the prevailing party) shall be paid as the arbitrators
determine. The decision of the arbitrators shall be final, and judgment thereon
may be entered by any court of competent jurisdiction. Notwithstanding this,
application may be made to any court for a judicial acceptance of the award or
order of enforcement. In the event of any dispute relating to patent
infringement, validity or enforceability, the parties agree to waive their
respective rights to a jury trial.

         IN WITNESS WHEREOF, the parties hereto have caused their duly
authorized officers to execute and acknowledge this Agreement as of the
Effective Date. This Agreement may be executed in one or more counterparts, each
of which shall be an original instrument, but all of which together shall
constitute a single agreement creating one set of rights and obligations.

Horizon Pharmaceutical Corporation:         Penwest Pharmaceuticals Co.:

By:                                         By:
   --------------------------------             -------------------------
   Brent Dixon                                  Tod R. Hamachek
   President                                    Chairman and
                                                Chief Executive Officer

Address:                                    Address:

660 Hembree Parkway                         2981 Route 22

Suite 106                                   Patterson, NY 12563

Roswell, GA 30076                           FAX: (914) 878-3420

FAX: (770) 442-9594                         Attn: Michael T. Mallon

Attn: Brent Dixon

                                      -25-
<PAGE>   26

IN WITNESS WHEREOF, the parties hereto have caused their duly authorized
officers to execute and acknowledge this Agreement as of the Effective Date.
This Agreement may be executed in one or more counterparts, each of which shall
be an original instrument, but all of which together shall constitute a single
agreement creating one set of rights and obligations.

Horizon Pharmaceutical Corporation:         Penwest Pharmaceuticals Co.:

By:                                         By:
   --------------------------------             -------------------------
   Brent Dixon                                  Tod R. Hamachek
   President                                    Chairman and
                                                Chief Executive Officer

Address:                                    Address:

660 Hembree Parkway                         2981 Route 22

Suite 106                                   Patterson, NY 12563

Roswell, GA 30076                           FAX: (914) 878-3420

FAX: (770) 442-9594                         Attn: Michael T. Mallon

Attn: Brent Dixon

                                      -26-
<PAGE>   27

                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

                                    Exhibit A

                               DESIGNATED PRODUCT

[***] form of a controlled-release pharmaceutical for oral administration in
humans in a 24 hour release form in a [***] strength that (a) combines a racemic
mixture of [***] with TIMERx and other excipients and (b) is eligible for
approval, or has been approved, by the FDA under an NDA.

                                       A-1
<PAGE>   28

                                    Exhibit B

                                    NET SALES

         "Net Sales" shall mean gross invoice price for sales by Horizon or its
Affiliates or sublicensees to unrelated third parties ("Customers"), less
deductions for (to the extent such amounts are included in the gross invoiced
sales price for the Designated Product) (a) statutory or contractual liability
for rebates to any governmental entity, rebates paid pursuant to the Medicaid
Rebate legislation, and any state and local governmental rebate programs; (b)
cash discounts generally available at the time of sale; (c) adjustments for
allowances or credits for returned Designated Product, free Designated Product
provided in lieu of discounts or rebates, damaged Designated Product, commercial
rebates, chargebacks, or trade discounts, whether or not paid directly to the
Customer; and (d) sales, excise, turnover, inventory, value-added, and similar
taxes and duties assessed on the sale of Designated Product. Notwithstanding the
foregoing, no discount, allowance, rebate, management fee, wholesaler
chargeback, or any similar amount however designated, that is given or
associated with the purchase by the Customer or its affiliates or associates of
any product other than the Designated Product, or with the purchase or provision
of any service, shall be taken into consideration in calculating any deductions
from the gross invoice. To the extent any of the amounts described in the
immediately preceding sentence are afforded to a Customer prior to the
calculation of the gross invoice price, such gross invoice price shall be
increased to reflect such amounts, solely for purposes of the calculation of Net
Sales under this Agreement. In the case of Designated Product sold to any
customer together with other products or services, the price of such Designated
Product, solely for purposes of the calculation of Net Sales under this
Agreement, shall be deemed to be no less than the price at which Designated
Product would be sold in a similar transaction to a customer not also purchasing
other products or services.

                                      B-1
<PAGE>   29

                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

                                    Exhibit C

                                 PENWEST PATENTS

<TABLE>
<CAPTION>

U.S. Patent                 Date                              Title              Inventor

Number
<S>                        <C>              <C>               <C>                <C>

[***]                      [***]            [***]             [***]                [***]
</TABLE>

                                      C-1
<PAGE>   30

                                    Exhibit D

                              PENWEST TRADEMARK(S)

TIMERx(R) Oral Delivery System

                                      D-1
<PAGE>   31

                                    Exhibit E

                                 SPECIFICATIONS

                                (to be attached)

                                      E-1
<PAGE>   32

                                    Exhibit F

                         DEVELOPMENT TASKS AND SCHEDULE

                                   (attached)

                                     Page 1
<PAGE>   33

                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

<TABLE>
<CAPTION>

----------------------------------------------------------------------------------------------------------------------------------
                                              TIMERx - [***] Development Plan - DRAFT

                                                      Effective March 25,1999
----------------------------------------------------------------------------------------------------------------------------------
  ID                 Task Name    Duration     Start        Finish      December      January     February       March        April
  <S>                <C>          <C>          <C>          <C>         <C>           <C>         <C>            <C>          <C>
----------------------------------------------------------------------------------------------------------------------------------
   1                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
   2                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
   3                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
   4                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
   5                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
   6                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
   7                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
   8                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
   9                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
  10                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
  11                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
  12                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
  13                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
  14                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
  15                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
  16                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
  17                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
  18                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
  19                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
  20                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
  21                   [***]       [***]       [***]                                                                          [***]
----------------------------------------------------------------------------------------------------------------------------------
</TABLE>

<TABLE>

<S>                   <C>          <C>         <C>                      <C>                 <C>                        <C>
Project               Task         Graphic     Summary                  Graphic             Rolled Up Progress         Graphic
Date:  Thu 3/25/99    Progress     Graphic     Rolled Up Task           Graphic
                      Milestone    Graphic     Rolled Up Milestone      Graphic
</TABLE>

                                     Page 1
<PAGE>   34

                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

                     TIMERx - [***] Development Plan - DRAFT

                            Effective March 25, 1999

<TABLE>
<CAPTION>

-----------------------------------------------------------------------------------------------------------------------------------
  ID                 Task Name    Duration     Start        Finish      December      January     February      March       April
  <S>                <C>          <C>          <C>          <C>         <C>           <C>         <C>           <C>         <C>
----------------------------------------------------------------------------------------------------------------------------------
  22                   [***]        [***]      [***]        [***]
----------------------------------------------------------------------------------------------------------------------------------
  23                   [***]        [***]      [***]        [***]
----------------------------------------------------------------------------------------------------------------------------------
  24                   [***]        [***]      [***]        [***]
----------------------------------------------------------------------------------------------------------------------------------
  25                   [***]        [***]      [***]        [***]
----------------------------------------------------------------------------------------------------------------------------------
  26                   [***]        [***]      [***]        [***]
----------------------------------------------------------------------------------------------------------------------------------

</TABLE>

<TABLE>

<S>                    <C>          <C>        <C>                  <C>                      <C>                      <C>
Project                Task         Graphic    Summary              Graphic                  Rolled Up Progress       Graphic
Date:  Thu 3/25/99     Progress     Graphic    Rolled Up Task       Graphic
                       Milestone    Graphic    Rolled Up Milestone  Graphic
</TABLE>

                                     Page 2
<PAGE>   35

<TABLE>
<CAPTION>

----------------------------------------------------------------------------------------------------------------------------------
         May        June       July       August       September       October          November          December          January
<S>      <C>        <C>        <C>        <C>          <C>             <C>              <C>               <C>               <C>
----------------------------------------------------------------------------------------------------------------------------------

----------------------------------------------------------------------------------------------------------------------------------
</TABLE>

<TABLE>

<S>                      <C>          <C>            <C>                         <C>               <C>                     <C>
  Project                Task         Graphic        Summary                     Graphic           Rolled Up Progress      Graphic
  Date:  Thu 3/25/99     Progress     Graphic        Rolled Up Task              Graphic
                         Milestone    Graphic        Rolled Up Milestone         Graphic
</TABLE>

                                     Page 1
<PAGE>   36

<TABLE>
<CAPTION>

----------------------------------------------------------------------------------------------------------------------------------
         May        June       July       August       September       October          November          December          January
<S>      <C>        <C>        <C>        <C>          <C>             <C>              <C>               <C>               <C>
----------------------------------------------------------------------------------------------------------------------------------

----------------------------------------------------------------------------------------------------------------------------------
</TABLE>

<TABLE>

  <S>                    <C>          <C>            <C>                         <C>               <C>                     <C>
  Project                Task         Graphic        Summary                     Graphic           Rolled Up Progress      Graphic
  Date:  Thu 3/25/99     Progress     Graphic        Rolled Up Task              Graphic
                         Milestone    Graphic        Rolled Up Milestone         Graphic
</TABLE>

                                     Page 2
<PAGE>   37

<TABLE>
<CAPTION>

----------------------------------------------------------------------------------------------------------------------------------
     February      March       April        May        June        July         August       September       October       November
----------------------------------------------------------------------------------------------------------------------------------
<S>               <C>          <C>          <C>        <C>         <C>          <C>          <C>             <C>           <C>

----------------------------------------------------------------------------------------------------------------------------------
</TABLE>

<TABLE>

  <S>                     <C>            <C>            <C>                       <C>              <C>                     <C>
  Project                 Task           Graphic        Summary                   Graphic          Rolled Up Progress      Graphic
  Date:  Thu 3/25/99      Progress       Graphic        Rolled Up Task            Graphic
                          Milestone      Graphic        Rolled Up Milestone       Graphic
</TABLE>

                                     Page 3
<PAGE>   38

<TABLE>
<CAPTION>

----------------------------------------------------------------------------------------------------------------------------------
     February      March       April        May        June        July         August       September       October       November
----------------------------------------------------------------------------------------------------------------------------------
<S>                <C>         <C>          <C>        <C>         <C>          <C>          <C>             <C>           <C>

----------------------------------------------------------------------------------------------------------------------------------
</TABLE>

<TABLE>
  <S>                     <C>            <C>            <C>                       <C>              <C>                     <C>
  Project                 Task           Graphic        Summary                   Graphic          Rolled Up Progress      Graphic
  Date:  Thu 3/25/99      Progress       Graphic        Rolled Up Task            Graphic
                          Milestone      Graphic        Rolled Up Milestone       Graphic
</TABLE>

                                     Page 4
<PAGE>   39

                                    Exhibit G

                                  MINIMUM SALES

The "Minimum Sales" shall be equal to the level of Net Sales of the Designated
Product for each of the years following the Approval Date set forth in the table
below.

<TABLE>
<CAPTION>

                  Year                                 Minimum Sales
                  ----                                 -------------

                  <S>                            <C>
                    1                             one million U.S. dollars
                                                      (US $1,000,000)

                    2                            three million U.S. dollars
                                                      (US $3,000,000)

                    3                            seven million U.S. dollars
                                                      (US $7,000,000)

               4 and each                         ten million U.S. dollars
             subsequent year                          (US $10,000,000)
</TABLE>

                                     Page 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}]]